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ABSTRACT 
 
After completing primary treatment, childhood brain tumor patients enter a follow-up 
phase. Follow-up is needed for two main reasons; to detect relapse and to diagnose 
late side effects. The overall aims of this thesis were; 1) To describe and analyze the 
pattern of relapse after treatment for medulloblastoma  the most common malignant 
brain tumor in childhood  with the aim to find potentially successful relapse 
treatment and; 2) To investigate ways to lessen the side effects of brain tumor 
treatment, especially the cognitive side effects.  
Methods: The long-term outcome of 338 medulloblastoma patients enrolled in the 
HIT-SIOP-PNET4 trial was investigated, with a focus on relapse diagnosis, pattern 
of relapse, and treatment of relapse. In a separate randomized, single-center, single-
blinded, pseudo crossover study, the potential benefit of physically active video 
gaming in childhood brain tumor survivors was investigated. Thirteen children, all 
previously treated with cranial radiotherapy, were randomized to either active video 
gaming (with weekly internet-based coaching sessions) followed by a waiting list 
period, or these periods in reverse order. They were assessed before and after each 
period, with measures of cognition, motor function and activities of daily living 
(ADL). Finally, in a rodent model the potentially protective effect of post-irradiation 
hypothermia on the neurogenic areas of the brain  the subventricular zone (SVZ) 
and the granule cell layer (GCL) of the hippocampus  was examined. Young rats 
were randomized to either normothermia or hypothermia for eight hours post-
irradiation, or a control group. Their brains were examined one week later, measuring 
the SVZ and GCL areas, and counting the number of proliferating cells and 
microglia.  
Results and conclusions: The ultimately grim prognosis for patients with recurrent 
medulloblastoma, irrespective of treatment, is confirmed. Surgery for histological 
diagnosis and research should be encouraged, and can in selected cases prolong 
survival, but new treatment options are needed. Active video gaming improves body 
coordination and the execution of ADL. Positive effects on cognition is a possibility, 
although not confirmed in this pilot study. Hypothermia after irradiation of the brain 
has a protective effect on the SVZ, but not the GCL, one week post-irradiation. The 
long term and functional effect of this finding needs further exploration, together 
with studies of the effect of hypothermia on brain tumors.  
Keywords: medulloblastoma, relapse, radiotherapy, cognition, exercise therapy, 
video games, hypothermia, pediatric, brain tumor ISBN: 978-91-629-0131-8 
 SAMMANFATTNING PÅ SVENSKA 
När barn med hjärntumör är färdigbehandlade påbörjas en uppföljningsfas, av 
två viktiga skäl: för att upptäcka eventuella återfall och för att upptäcka sena 
biverkningar. Målsättningen med denna avhandling var dels att beskriva och 
analysera återfall av medulloblastom, den vanligaste elakartade hjärntumören 
hos barn, dels att undersöka sätt att mildra de långsiktiga (kognitiva) 
biverkningarna som barn med hjärntumör ofta drabbas av.  
I avhandlingen presenteras resultat avseende överlevnad hos 338 patienter 
som behandlats för medulloblastom i studien HIT-SIOP-PNET4. Hos de 72 
patienter som fick återfall beskrivs diagnostik, återfallsmönster, behandling 
och prognos. I en separat studie av 13 barn som fått strålbehandling för en 
hjärntumör undersöktes om regelbundet spelande av fysiskt aktiverande 
dataspel (Nintendo Wii) kunde påverka motorik, kognition, aktiviteter i 
dagliga livet (ADL) och aktivitetsnivåer. I denna randomiserade 
singelblindade studie fick barnen antingen börja med fysiskt aktivt 
dataspelande (med veckovis internetbaserat coachningstöd) följt av en 
”vänteperiod”, eller det omvända. De utvärderades före och efter varje period 
med hjälp av kognitiva och motoriska tester samt test avseende ADL-
förmåga. Slutligen undersöktes i en djurmodell om generell nedkylning 
(hypotermi) kunde skydda de nervcellsbildande (neurogena) områdena i den 
unga hjärnan från att skadas av joniserande strålning. Unga råttor 
randomiserades till tre grupper, normal kroppstemperatur alternativt 
nedkylning under åtta timmar efter en stråldos mot vänster hjärnhalva, eller 
till en kontrollgrupp. En vecka senare undersöktes de neurogena områdena i 
hjärnan, den subventrikulära zonen (SVZ) och den subgranulära zonen i 
korncellslagret (eng: granule cell layer, GCL) i hippocampus. Områdenas 
areor mättes och antalet celler i celldelning samt antalet inflammatoriska 
celler (mikroglia) räknades. 
 
Slutsatser: Återfallsrisken efter behandling för medulloblastom är ca 20 %. 
Återfall medför en mycket dålig prognos, trots ibland intensiva 
behandlingsförsök. I utvalda fall kan kirurgi förlänga överlevnaden. Nya 
läkemedel eller angreppssätt behövs. Fysisk aktiverande dataspel förbättrar 
kroppskoordinationen samt ADL-förmågan hos barn som behandlats för 
hjärntumör. Positiva kognitiva effekter är en möjlighet men kunde inte säkert 
påvisas i denna pilotstudie. Hypotermi efter strålning skyddar cellerna i SVZ 
men inte i GCL, en vecka efter strålningen. Betydelsen av detta för den 
kognitiva förmågan, liksom effekten av hypotermi på tumörer behöver 
studeras ytterligare i framtida studier. 
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ADD Attention deficit disorder 
ADL Activities of daily living 
AMPS Assessment of Motor and Process Skills 
AT/RT Atypical Teratoid/Rhabdoid Tumor 
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EFS Event free survival 
EE Energy expenditure 
FSIQ Full-Scale Intelligence Quotient 
ETMR Embryonal Tumor with Multi-layered Rosettes 
GTR Gross total resection 
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Iba1 Ionized calcium-binding adapter molecule 1 
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i.t. Intrathecal 
MBEN Medulloblastoma with Extensive Nodularity 
MET Metabolic Equivalent of Task 
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MRI Magnetic resonance imaging 
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MYC V-MYC avian myelocytomatosis viral oncogene homolog 
MYCN V-MYC avian myelocytomatosis viral oncogene 
neuroblastoma-derived homolog 
NPC Neural progenitor cell 
n.s. Non-significant 
OS Overall survival 
PAAC Physical activity across the curriculum 
PBS Phosphate-buffered saline 
PF Posterior fossa 
PFS Progression-free survival 
PNET Primitive neuroectodermal tumor 
PHH3 Phosphorylated-Histone H3 
QoL Quality of Life 
RAVLT Rey Auditory Verbal Learning Test 
ROS Reactive oxygen species 
SD Standard deviation 
SHH Sonic hedgehog 
SMN Second malignant neoplasm 
SRM Standardized response mean 
stPNET Supratentorial PNET 
STRT Standard radiotherapy 
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WISC-IV Wechsler Intelligence Scale for Children-version IV 
WNT Wingless-related integration site 
WT Wild type 
 
  
vi 
DEFINITIONS IN SHORT 
Active video gaming Video gaming requiring physical activity 
(beyond that of conventional hand-controlled 
games), sometimes referred to as exercise 
gaming or exergaming 
Cognition The mental action or process of acquiring 
knowledge and understanding through 
thought, experience, and the senses (Oxford 
Dictionaries, 2016) 
Epigenetics Mitotically heritable changes in gene 
expression that are not accompanied by 
modifications in primary DNA sequence 
(Northcott et al. 2010) 
Executive function A psychological construct of the cognitive 
processes responsible for planning, 
sequencing, and controlling goal-directed 
behavior (Banich 2009) 
Exergaming A portmanteau of “exercise” and “gaming” 
Exercise Exercise is a subset of physical activity that is 
planned, structured, and repetitive with the 
objective of improving or maintaining 
physical fitness (Caspersen et al. 1985) 
Physical activity Any bodily movement produced by skeletal 
muscles that requires energy expenditure 
(WHO) 
Standardized Response 
Mean (SRM) 
Effect size measure, defined as the ratio 
between the mean change score and the 
standard deviation of that change score within 
the same group 
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1 INTRODUCTION 
Every year in Sweden, around 300 children are diagnosed with a childhood 
cancer, and 28 % of them have a tumor in the central nervous system, CNS 
(Gustafsson et al. 2013). The mean annual incidence rate in the Nordic 
countries has been estimated to 4.2/100 000, and has remained stable for at 
least 20 years (Schmidt et al. 2011). The prognosis for CNS tumors has 
improved during the last decades, and 10 year overall survival (OS) in 
Sweden is now exceeding 70%, although the prognosis is highly dependent 
on the histopathological diagnosis and tumor location, as well as treatment 
(Lannering et al. 2009).  
Despite the improvement in prognosis, cancer is still the major cause of death 
in Swedish children aged 1-14 years, with CNS tumors being the most 
common cancer type leading to death in this age group (Socialstyrelsen 
2016). Malignant brain tumors have a worse prognosis, and curative 
treatment usually requires a combination of neurosurgery, chemotherapy 
and/or radiotherapy. For the survivors, cure often comes with a cost of long-
term side effects. This means that annually in Sweden, around 50-60 children 
and adolescents join an increasing group of pediatric brain tumor survivors. 
Finding effective rehabilitation therapies that promote neural recovery, as 
well as preventive programs, will therefore be increasingly important. 
If a tumor relapses after primary treatment, chances of cure are reduced. The 
additional relapse treatment required, adds to the risk for late side effects 
(Conklin et al. 2008). The balancing of increased treatment intensity, with the 
aim of increasing the chance for cure, versus the risk for severe long-term 
side effects is a major challenge in all pediatric oncology and especially in 
pediatric neuro-oncology. Without cure there are no long-term side effects, 
but if cure is achieved at the price of a functioning brain there might be life, 
but of poor quality. Despite the sometimes severe impact of the 
neurocognitive side effects, there have been few studies of methods to 
remediate or prevent them, and even fewer empirically supported 
interventions available in clinical practice. 
 
1.1 Brain tumors in children 
A “brain tumor” is not a single entity, and children are not adults. As for 
many childhood cancers, the type and distribution of brain tumors differs 
Brain tumors in children 
8 
from those of adults (Ostrom et al. 2013). The most recent update of the 
WHO classification; the 2016 World Health Organization Classification of 
Tumors of the Central Nervous System, lists >130 different entities and 
variants of brain tumors. In this classification update, brain tumors are for the 
first time classified not only according to their histopathological features, but 
with the option to also incorporate molecular findings, integrating the 
tumors’ phenotypic and genotypic features (Louis et al. 2016). The WHO 
classification includes a grading of the malignancy of a tumor type according 
to features suggesting malignancy, such as pleomorphic nuclei, high mitotic 
rate, and vascular invasion, ranging from I-II (non-malignant) to III and IV 
(malignant). The grading can be used as a means of predicting the biological 
behavior of a neoplasm (Louis et al. 2007). On top of this 
histological/molecular classification, the tumor location in the brain is a 
crucial factor, with implications on symptoms, treatment strategy and 
prognosis. Thus, a non-malignant tumor such as a pilocytic astrocytoma 
(WHO grade I) can have an excellent prognosis when located at a site where 
it is amenable to surgical removal (such as the cerebellum), and a poorer 
prognosis when located in a more sensitive area, such as the thalamus or 
basal ganglia (Gnekow et al. 2012).  
 Figure 1.Childhood CNS tumors in Sweden 1984-2010. (Gustafsson et al. 2013) 
30%
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The childhood brain tumors (Figure 1) can be roughly divided into tumors of 
glial origin and those of non-glial origin (Northcott et al. 2015). Examples of 
glial tumors include astrocytomas, ependymomas, oligodendrogliomas, and 
mixed glial/neuronal tumors (e.g. gangliogliomas). Examples of non-glial 
tumor types are embryonal tumors, such as medulloblastomas, atypical 
teratoid/rhabdoid tumors (AT/RTs) and Embryonal Tumors with Multi-
layered Rosettes (ETMRs), but also craniopharyngeomas, and germ cell 
tumors, among others. The classification is constantly evolving and changes 
over time, as we gain more knowledge. For example, in the current WHO 
classification, primitive neuroepithelial tumors (PNET) are no longer 
recognized as an entity and the PNET terminology is no longer used (Louis et 
al. 2016). This change reflects the emerging evidence, using e.g. methylation 
profiling, that most “PNETs” are more commonly related to other tumor 
types (such as glioblastomas or ependymomas), than to each other (Schwalbe 
et al. 2013, Danielsson et al. 2015). There are data however, suggesting the 
existence of a true “PNET” group of tumors (Sturm et al. 2016). 
The age distribution of diagnosed childhood CNS tumors (between ages 1 to 
<15 years) is fairly even, without apparent age peaks (Gustafsson et al. 
2013). Just over 50 % of all pediatric CNS tumors are located in the posterior 
fossa (PF), the majority of these are in the cerebellum (41 %), and a smaller 
fraction in the brainstem (10-13 %). The remainder are found in the cerebral 
hemispheres (21-24 %), the midbrain (13-25 %), and spinal cord (3 %). 
(Lannering et al. 1990b, Kaatsch et al. 2001). 
 
1.2 Pediatric brain tumor treatment 
Finding a brain tumor does not automatically mean it must be treated. 
Treatment decisions are based on the (presumed or histologically proven) 
tumor type, tumor location, symptoms and the patient´s age. In selected 
cases, tumor surveillance by repeated magnetic resonance imaging (MRI) can 
be justified (Ali et al. 2014). This option is mainly used in cases of slow-
growing (low-grade) tumors in neurologically sensitive areas, such as the 
tectal plate (Stark et al. 2005). In the majority of brain tumor cases, treatment 
is necessary without further delay. The first option to consider is to surgically 
remove the tumor, completely if possible, partially if not. In sensitive areas of 
the CNS only a biopsy might be achievable. A major advantage with an 
initial surgical procedure is obtainment of tumor tissue, leading to a 
Brain tumors in children 
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histopathological diagnosis. The histopathological diagnosis is the foundation 
for further treatment decisions, together with tumor location, tumor stage 
(presence or absence of metastases), result of surgery, and the patient´s age.  
Staging of CNS tumors is usually done by MRI of the brain and spine, 
together with cerebrospinal fluid (CSF) cytology. Some tumor types (germ 
cell tumors) secrete substances that can be detected in the CSF and/or blood, 
and used as diagnostic/prognostic tumor markers. If the tumor is completely 
resected, and is non-malignant (WHO grade I-II), no further treatment is 
usually required (Fisher et al. 2001), although exceptions to this rule exist. 
Sub-totally resected, non-malignant tumors can benefit from additional 
therapy, but a period of watchful waiting is often prudent (Fisher et al. 2008).  
The malignant tumors (WHO grade III-IV) cannot be cured by surgery alone, 
even if a (macroscopically) complete resection is achieved. Malignant tumors 
grow in an infiltrative manner that prevents microscopically complete 
resections, without causing inacceptable neurologic damage. They also have 
a propensity to metastasize, usually within the CNS. Therefore they are 
treated with surgery together with chemotherapy and/or radiotherapy, in 
order to get rid of infiltrating tumor cells as well as metastases. An example 
of such combined therapy is the treatment for medulloblastoma. 
 
1.3 Medulloblastoma 
The term medulloblastoma was coined by Bailey and Cushing around 1925, 
when they described “a very cellular tumor of a peculiar kind”, usually 
located in the central part of the cerebellum, just over the 4th ventricle. 
(Bailey and Cushing 1925). Medulloblastoma is the most common malignant 
brain tumor in children, diagnosed in about 15-20 % of children with brain 
tumors (Kaatsch et al. 2001, Lannering et al. 2009, Ostrom et al. 2013). Most 
cases occur during the first decade of life, with a peak incidence between 5-9 
years of age (Lannering et al. 2009, Ostrom et al. 2013), but it can also be 
diagnosed in infants, teenagers and young adults. Boys are more commonly 
affected, about 1.4-1.5 times as commonly as girls (Lannering et al. 2009, 
Kool et al. 2012). Metastases are present at primary diagnosis in ~24 % of all 
cases (Kool et al. 2012).  
Histological subgroups The four histological medulloblastoma 
subgroups defined in the current WHO classification (and their relative 
frequency) are: classic medulloblastoma 70 % (CMB), desmoplastic/nodular 
Magnus Sabel 
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16 % (DNMB), medulloblastoma with extensive nodularity (MBEN), and 
large cell/anaplastic 10 % (LCA) (Kool et al. 2012, Louis et al. 2016). 
Medulloblastomas of the large cell or anaplastic histological subtype have 
been found to be associated with poorer survival, and these histologies are 
now regarded as high risk factors (Brown et al. 2000, Eberhart et al. 2002).  
Age The significance of lower age (< 3 years) as an independent negative 
prognostic risk factor is unclear (Packer et al. 2003). In many studies, 
children < 3 years have a worse prognosis compared to older children (Evans 
et al. 1990, Zeltzer et al. 1999, Packer et al. 2001), but comparisons are 
confounded by differences in therapy (e.g. no radiotherapy or lower 
radiotherapy dose given to the younger children), differences in M-stage 
between groups, and the inclusion of (poor prognostic) AT/RTs, in studies of 
the earlier era  before this diagnosis was described (Rorke et al. 1996). 
Younger children have a greater risk for cognitive impairment after 
radiotherapy, as discussed below. Looking solely at younger children treated 
without radiotherapy, the DNMB/MBEN histological subtypes have a better 
prognosis (Rutkowski et al. 2010).  
 
Stage and risk stratification A staging classification (Table 1) was 
developed by Chang et al. in the 1960s (Chang et al. 1969), and risk group 
stratification according to Chang M-stage and other clinical biomarkers, (i.e. 
age at diagnosis, extent of surgical resection), has been used since the 1990s 
(Gottardo et al. 2014). The average or standard risk group, has been defined 
by: age >3 years, gross total resection (GTR) of the tumor, (or a tumor 
residual of ≤ 1.5 cm2), no evidence of metastatic disease (= Chang stage M0), 
and no other high risk factors present (Ellison et al. 2003).  
Table 1. Chang staging classification for metastasis in medulloblastoma 
Stage Definition 
Metastasis  
M0 No evidence of gross subarachnoid or hematogenous metastasis. 
M1 Microscopic tumor cells found in cerebrospinal fluid. 
M2 Gross nodular seeding demonstrated in the cerebellar, cerebral 
subarachnoid space, or in the third or lateral ventricles 
M3 Gross nodular seeding in spinal subarachnoid space 
M4 Extraneural metastasis 
 
Table derived from Chang et al. 1969 
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Molecular subgroups Based on the almost identical appearance 
(determined by light microscopy and immunohistochemical techniques) of 
tumors originating in different parts of the CNS, the concept of PNET was 
formed, suggesting that medulloblastomas were a subgroup of PNETs located 
in the cerebellum (Becker and Hinton 1983, Rorke 1983). This concept 
remained controversial however, especially since different responses to 
therapy (and prognosis) were seen for PNETs in different areas of the brain 
(Rorke et al. 1997). Using gene expression data, Pomeroy et al. showed that 
PNETs from different areas of the brain had different gene expression 
profiles, and that medulloblastomas could be separated from supratentorial 
PNETs and AT/RTs using the molecular profile (Pomeroy et al. 2002). They 
also described a subgroup of medulloblastomas (mainly of the desmoplastic 
histological subtype) with a distinct gene expression profile characterized by 
activation of the sonic hedgehog (SHH) signaling pathway, and showed that 
gene expression data could be used as a prognostic tool (Pomeroy et al. 
2002).  
In time, several molecular subgroups of medulloblastoma were identified by 
different researchers (Thompson et al. 2006, Kool et al. 2008, Fattet et al. 
2009, Cho et al. 2011, Northcott et al. 2011), and in a consensus statement 
2012, the four principal molecular medulloblastoma subgroups were 
described and named: Wnt, Shh, Group 3, and Group 4 (Taylor et al. 2012). 
In the revised WHO classification from 2016 medulloblastomas can now, in 
addition to the histologically defined variant, also be genetically or 
epigenetically defined as either WNT-activated medulloblastomas, SHH-
activated medulloblastomas (TP-53 mutant or TP-53 wildtype) and non-
WNT/non-SHH medulloblastomas (i.e. Group 3 and group 4 
medulloblastomas) (Louis et al. 2016). 
Molecular subgroups together with other molecular risk factors are now used 
in on-going clinical trials, and will be increasingly important in both 
diagnosis and treatment stratification in future studies (Gajjar et al. 2004, 
Pfister et al. 2009). The clinical and biological risk factors used so far, will 
need to be validated in the context of medulloblastoma subgroups. In this 
new era, metastatic status and medulloblastoma subgroup seem to be strong 
predictive biomarkers. Previously reported biological prognostic biomarkers 
are sometimes subgroup driven (e.g. chr6 loss in WNT medulloblastomas), 
and sometimes only relevant in a given subgroup (Zhukova et al. 2013, Shih 
et al. 2014). A new proposal on risk factor stratification for clinical trials, 
combining traditional clinical risk factors with subgroups and 
molecular/genetic factors, was recently published (Ramaswamy et al. 2016b), 
Table 2. 
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Table 2. Proposed risk stratification for non-infant childhood 
medulloblastoma, (Ramaswamy et al. 2016a) 
 
1.3.1 Medulloblastoma treatment 
Neurosurgical treatment for medulloblastoma was pioneered by Harvey 
Cushing and it was soon recognized that more extensive surgery rather than a 
biopsy could prolong survival, but only for a limited time (from 6 to 17 
months) (Cushing 1930). It was also early noted that radiotherapy prolonged 
survival (Bailey and Cushing 1925), and Bailey suggested that craniospinal 
irradiation (CSI) was necessary to counter the tumor’s propensity to recur 
distally in the CNS, far from the original site (Bailey 1930). In an early 
Swedish report, Olivecrona and Lysholm described the treatment of various 
gliomas with surgery and irradiation, including an 11 year old boy with a 
very cellular tumor “closely resembling a type of gliomatous tumor 
 WNT SHH Group 3 Group 4 
     
Low risk < 16 years    
     
Standard risk  TP53 wt (somatic 
or germline) 
No MYCN 
amplification 
Non-metastatic 
All of the following: 
No MYCN-
amplification 
Non-metastatic 
All of the 
following: 
Non-metastatic 
Chr.11 loss 
     
High risk  One or both: 
Metastatic 
MYCN 
amplification 
 Metastatic 
     
Very high 
risk 
 TP53 mutation 
(metastatic or non-
metastatic) 
Metastatic  
     
Unknown Metastatic  Non-metastatic with 
MYC amplification 
Anaplasia 
Isochromosome 17q 
Anaplasia 
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designated by Bailey and Cushing as medulloblastoma” (Olivecrona and 
Lysholm 1926).  
For decades to follow, medulloblastoma was a fatal disease for all but a few 
patients (Ingraham et al. 1948), but improvements in radiotherapy technique, 
surgical and anesthetics procedures continued. The numbers of 
medulloblastoma survivors started to increase in the 1960-70s (Bloom et al. 
1969). New imaging techniques with computerized tomography (CT) and 
MRI also became available, improving diagnosis as well as tumor staging 
and risk grouping (Zimmerman et al. 1978, Kramer et al. 1991). Assigning 
patients to risk groups and the addition of adjuvant chemotherapy were also 
important steps.  
Evans and coworkers were among the first to demonstrate a survival benefit 
of radiotherapy and adjuvant chemotherapy in the treatment of high (poor) 
risk medulloblastoma (Evans et al. 1990). They reported an event free 
survival of 49 % in the chemotherapy group versus 0 % in the radiotherapy-
only group (p=0.006), although no benefit from chemotherapy was found in 
patients with less advanced disease. In a single-institution trial, the addition 
of chemotherapy to radiotherapy was found to significantly improve survival 
in poor-risk patients, compared to historical controls (Packer et al. 1991). 
Expanding on these encouraging results, a larger, three-institution trial, was 
conducted. Patients with high risk medulloblastoma received a combination 
of radiotherapy and chemotherapy, resulting in a 5-year progression-free 
survival (PFS) of 85% (Packer et al. 1994). The study also included some 
younger patients (<5 years) without high-risk disease, who received a lower 
dose of CSI (23.4 Gy) with promising results (Packer et al. 1994).  
Alarming reports of severe cognitive side effects from radiotherapy 
(discussed below) triggered research to find less toxic therapies, without 
jeopardizing the chance of cure. The POG 8631/CCG 923 study randomized 
standard risk medulloblastoma patients between “reduced-dose” CSI (23.4 
Gy) and “standard-dose” CSI (36 Gy)  both in combination with a posterior 
fossa boost up to 54 Gy  but found the reduced CSI dose to be inferior 
regarding survival (8-year EFS 52% vs 67%, p=0.080) (Thomas et al. 2000).  
However, another study in standard risk medulloblastoma also used reduced-
dose CSI (23.4 Gy, with a PF boost up to 54 Gy), but in combination with 
chemotherapy, and presented better survival with a 5-year PFS of 79% 
(Packer et al. 1999). The shift towards the current, lower “standard dose” for 
standard risk medulloblastoma of 23.4 Gy CSI had thus begun. The positive 
results of combining chemotherapy with the lower dose of 23.4 Gy CSI were 
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later confirmed in two large trials. The COG9961 study which used 23.4 Gy 
CSI and randomized between two different chemotherapy arms, resulted in a 
5-year EFS of 81% (irrespective of randomization arm) (Packer et al. 2006). 
Also the HIT-SIOP PNET4 trial, described below, demonstrated similar 
results (Lannering et al. 2012). In a retrospective study, the addition of 
chemotherapy to radiotherapy improved local control (100% for the 
combined-therapy group vs 75% in the group with radiotherapy only) 
(Christopherson et al. 2014). Although the significance of adding 
chemotherapy to radiotherapy has not been convincingly proven in 
randomized controlled trials (Michiels et al. 2015), there are several studies 
indicating a benefit of adding chemotherapy.  
In order to avoid the detrimental effects of radiotherapy there has been a 
consensus within the medical community to avoid radiation therapy in 
younger children, (below 3-5 years of age), and to treat these children with 
chemotherapy alone (± high dose chemotherapy with stem cell rescue, 
HDSCR) (Grill et al. 2005, von Bueren et al. 2011, Cohen et al. 2015). For a 
subset of infants (i.e. with DNMB/MBEN histology) this strategy has been 
successful (Rutkowski et al. 2010). 
1.3.2 HIT-SIOP PNET4  
The HIT-SIOP PNET4 trial (2001-2006) was a multinational collaborative 
European study with patients from 120 centers in Germany, France, Italy, 
UK, Austria, Spain, The Netherlands, Sweden, Norway and Denmark. It 
included 338 patients (211 male, 127 female), aged 4 to 21 years, with a non-
metastatic medulloblastoma (i.e. no metastases on craniospinal MRI and 
negative CSF cytology). A postoperative residual tumor was allowed, but 
second surgery was recommended if it was >1.5 cm2. After an amendment in 
2003, patients with large-cell/anaplastic histology tumors were no longer 
included, due to reports of inferior outcome in these patients with standard-
risk therapy (Eberhart et al. 2002).  
Patients were randomized to either standard radiotherapy (STRT, n=169) 
(23.4 Gy to the craniospinal axis and 54 Gy to the whole posterior fossa over 
42 days, in 30 fractions of 1.8 Gy, one fraction per day) or hyperfractionated 
radiotherapy (HFRT, n=169) (1 Gy/fraction, two fractions per day up to 36 
Gy to the craniospinal axis, 60 Gy to the posterior fossa, and an additional 
boost to a total of 68 Gy to the tumor bed). Patients in both randomization 
arms received concomitant chemotherapy with weekly vincristine during 
radiotherapy, followed by adjuvant chemotherapy (eights cycles of cisplatin-
CCNU-vincristine every six weeks), starting 6 weeks after the end of 
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radiotherapy. Tumor histology (99.4 % centrally reviewed) identified classic 
medulloblastoma in 81 %, desmoplastic-nodular medulloblastoma in 14 % 
and large-cell/anaplastic medulloblastoma in 5 % of cases. Out of 254 
assessable tumors, 58 (22.8 %) were WNT-positive medulloblastomas by β-
catenin IHC, 31/195 (15.9 %) harbored CTNNB1 activating mutations 
(Clifford et al. 2015). On central review of pre- and post-operative MRIs 
(performed in 94 % of cases), 31/338 patients (9 %) had a residual tumor 
>1.5 cm2.  
No difference in survival was demonstrated after HFRT compared to STRT. 
After a median follow up of 4.8 years after diagnosis, the 5-year-EFS for all 
patients was 79 %, and the 5-year OS 86 %. The 5-year EFS was 78 % for 
the STRT arm and 81 % for the HFRT arm (p=0.9) (Lannering et al. 2012). 
Features significantly associated with inferior prognosis were the presence of 
a post-operative tumor residue >1.5 cm2 (n=31, p<0.01), and a delay in 
radiotherapy start >49 days after surgery (5-year EFS 0.67 vs 0.81, p=0.04) 
(Lannering et al. 2012). Patients with WNT-MB had favorable outcomes, 
although WNT-MB patients aged ≥16.0 years at diagnosis appeared to have a 
lower EFS than younger patients (p=0.058). In the true standard-risk cohort 
(i.e. after removal of patients with a tumor residue >1.5 cm2), tumors with 
chromosome 17 imbalances/diploid background were associated with a poor 
outcome (<60 % 5-year EFS), but tumors with MYC/MYCN amplification or 
LCA histology were not (Clifford et al. 2015). 
1.3.3 Medulloblastoma relapse 
Several studies have shown the prognosis of recurrent medulloblastoma after 
standard therapy (i.e. including radiotherapy) to be dismal (Torres et al. 1994, 
Bouffet et al. 1998, Pizer et al. 2011). In the French study, by Bouffet et al., 
median survival after progression was only five months after a variety of 
treatments including surgery, chemotherapy, radiotherapy and high dose 
chemotherapy (Bouffet et al. 1998). Histological subtype was not reported. 
Response to salvage therapy and solitary recurrence were clinical factors 
associated with longer survival after relapse, but only 2/46 relapsed patients 
remained alive, (only one disease-free), at the writing of the report (Bouffet 
et al. 1998). 
High dose chemotherapy with stem cell rescue (HDSCR) for recurrent brain 
tumors (including medulloblastoma) has been tried with some initially 
promising results (Finlay et al. 1996, Graham et al. 1997, Guruangan et al. 
1998). These studies, together with studies that followed, indicated a benefit 
of HDSCR in a subgroup of patients, e.g. patients never treated with 
Magnus Sabel 
17 
radiotherapy as part of their primary therapy, or patients with minimal 
residual disease responsive to chemotherapy (Dunkel et al. 1998, Butturini et 
al. 2009). There is one caveat however; in many studies the recurrences were 
treated with surgery and/or radiotherapy in addition to HDSCR, making the 
prognostic impact of HDSCR difficult to evaluate (Dunkel et al. 1998, 
Gururangan et al. 2008). In addition, several studies enrolled patients just 
prior to the initiation of HDSCR, and not immediately at the diagnosis of 
relapse, e.g. (Dunkel et al. 2010). With such a design, patients with chemo-
resistant disease or early disease progression are never enrolled and the 
benefit of HDSCR therefore overestimated, based on the total population of 
relapsing patients. This selection bias is a problem in several other studies 
and makes it difficult to estimate the true benefit of HDSCR, in the absence 
of randomized controlled trials comparing HDSCR to other therapies (Gajjar 
and Pizer 2010).  
Only a few national studies addressing treatment with HDSCR for recurrent 
medulloblastoma exist, but they can give an estimate of the benefit of 
HDSCR when considering the entire population of patients. The UK CCLG 
relapsed PNET study (2000-2007) enrolled 40 patients, (35 with recurrent 
medulloblastoma and five with stPNET), all but one previously treated with 
radiotherapy (Pizer et al. 2011). The study aimed to first achieve complete or 
near-complete remission, and then treat with HDSCR. Of the patients 
enrolled, only 22/40 (55 %) proceeded to the HDSCR phase. The remainder 
were withdrawn from the study, either due to lack of response to induction 
chemotherapy or other reasons, such as toxicity. At a median follow-up of 7.4 
years, only three MB patients were still alive. The 5-year EFS and OS was 
8.7 % and 8.2 % years respectively (Pizer et al. 2011).  
The German HIT-REZ-97 national study tested a non-randomized but 
stratified relapse protocol using either intensive chemotherapy with the 
addition of HDSCR to good responders (as a potentially curative therapy), or 
only oral chemotherapy as a palliative option (Bode et al. 2014). Of 72 
patients (87 % medulloblastomas) selected to receive the intensive 
chemotherapy option, only 27 (38 %) eventually received HDSCR. The 
median PFS was 11.6 months for the whole cohort, and 5-year PFS 0.5 %. In 
the HDSCR cohort the median PFS was 8.4 months, and 5-year PFS 0.1 %. 
Regarding OS, the median was 21.0 months for the whole cohort, and 5-year 
OS 16 %. In patients treated with HDSCR, the median OS was 20.2 months, 
and 5-year OS 17 %. There was no difference in survival when comparing 
good responders who did, or did not, receive HDSCR. A treatment related 
mortality of 8 % was reported. Increased toxicity is an obvious risk from 
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intensive therapies such as HDSCR, and many studies have reported even 
higher toxic death rates of 10-16 % (Bouffet et al. 1998, Dunkel et al. 2010). 
Oral chemotherapy regimens, e.g. with temozolomide, has been shown to 
provide some disease control, albeit not long-lasting. In a study by Cefalo et 
al., oral temozolomide gave a response rate of 42.5 %, but a disappointing 1-
year PFS of 7.5 % (Cefalo et al. 2014). Oral etoposide as single therapy has 
also been evaluated in small series, with similar but short-lived responses, 
and median survival times of 5.5 months from treatment initiation (Ashley et 
al. 1996, Chamberlain and Kormanik 1997). 
Low intensity multi-agent drug combinations, (often referred to as 
‘metronomic chemotherapy’) have been tried in smaller series of relapsed 
medulloblastoma, with some promising preliminary results (Sterba et al. 
2006, Peyrl et al. 2012). This approach, believed to function through anti-
angiogenesis which indirectly inhibits tumor growth, is currently being 
evaluated in the multinational MEMMAT trial. 
 
1.4 Long term side effects 
Survivors of pediatric brain tumors often suffer long term side effects. The 
risk for these side effects, and their character, depend on several factors. 
Treatment is one, but premorbid factors as well as damage from the tumor 
itself, also contributes (Iuvone et al. 2011). Before discussing the cognitive 
late effects, some other side effects are worth mentioning. Although not a 
complete list, late side effects include: impaired motor performance and other 
neurological sequelae (Lannering et al. 1990a, Aarsen et al. 2004, 
Oyharcabal-Bourden et al. 2005, Ullrich 2009, Piscione et al. 2014), epilepsy 
(Sonderkaer et al. 2003), endocrine deficiencies and perturbed growth 
(Gurney et al. 2003, Oyharcabal-Bourden et al. 2005, Chemaitilly et al. 
2015), impaired vision or visual field defects (Harbert et al. 2012), impaired 
hearing (Lannering et al. 1990a, Oyharcabal-Bourden et al. 2005), increased 
risk for second malignancies (Tsui et al. 2015), vasculopathy leading to 
increased risk for stroke (Gurney et al. 2003, Murphy et al. 2015), reduced 
muscle strength and fitness (Ness et al. 2010), and alopecia (Oyharcabal-
Bourden et al. 2005).  
Childhood brain tumor survivors often have deficits in activities of daily 
living (ADL) (Demers et al. 2016), and are (among childhood cancer 
survivors) the group most likely to report restricted abilities to perform 
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personal care, restricted abilities to do routine activities, restricted abilities to 
attend work or school, as well as performance limitations (Ness et al. 2005). 
In a small study (n=20) by Edelstein et al., 20 % of adult survivors of 
childhood medulloblastoma were dependent on caregivers for their daily care 
(Edelstein et al. 2011). On the other hand, 55 % were competitively 
employed or attended school full time. Studies of quality of life (QoL), have 
found radiotherapy and intelligence quotient (IQ) to be associated with lower 
health-related QoL (Reimers et al. 2009). In follow-up studies, brain tumor 
survivors were at increased risk for adverse outcomes such as unemployment, 
having a health condition affecting their ability to work, lower education 
level, lower income, and poorer health (Mostow et al. 1991, Boman et al. 
2010). Still, in the study by Mostow et al., 85 % of the survivors had some 
employment, and 80 % described their health as excellent or good, indicating 
the diversities within the brain tumor group (Mostow et al. 1991). Negative 
social consequences for brain tumor survivors have also been reported. Adult 
childhood brain tumor survivors were less likely to be married or to live in a 
relationship, and to have children of their own, compared to controls 
(Langeveld et al. 2003, Reimers et al. 2009). 
1.4.1 Cognitive side effects  
The prevalence of cognitive dysfunction in pediatric brain tumor patients 
ranges from 20-70 % (Lannering et al. 1990a, Aarsen et al. 2006, Brinkman 
et al. 2016), up to 100 % in selected subgroups (Glauser and Packer 1991). 
IQ has been the most common measure of general cognitive function. Most 
studies have found a lowered IQ score in survivors, 1-2 standard deviations 
below the expected mean (Saury and Emanuelson 2011).  
Intelligence quotient (IQ) 
The finding of lowered IQ is perhaps not surprising, since IQ is a compound 
of several different abilities. IQ can be measured by different scales, e.g. the 
Wechsler scales, with different scales for different age groups. These scales 
are regularly updated. The full-version or the abbreviated version of the 
Wechsler scales can be used. The Full-Scale IQ score is a composite of 
Verbal and Performance IQ scores, each with a normative mean of 100 and a 
standard deviation (SD) of 15. Verbal IQ is composed of several subtests that 
measure verbal comprehension and knowledge. Performance IQ includes 
subtests that measure visual-perceptual and nonverbal skills. In childhood 
brain tumor survivors, the non-verbal (performance) abilities are usually 
more affected than the verbal abilities (Grill et al. 1999, Mulhern et al. 1999, 
Kieffer-Renaux et al. 2000, Carpentieri et al. 2003, Reimers et al. 2003).  
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After radiotherapy, the IQ score decreases at a rate between 1.7 and 5 IQ 
points per year in different series (Copeland et al. 1999, Palmer et al. 2001, 
Ris et al. 2001, Spiegler et al. 2004, Saury and Emanuelson 2011, Ris et al. 
2013). Longitudinal studies suggest that IQ declines for the first 2-5 years 
after diagnosis, but the decline is attenuated 5-10 years after diagnosis 
(Palmer et al. 2003, Spiegler et al. 2004, Kieffer-Renaux et al. 2005, 
Edelstein et al. 2011). It seems the decline in IQ is not caused by loss of 
previously learnt skills, but rather a slower rate of acquiring new knowledge 
compared to healthy peers, so that patients lag behind more and more with 
time (Palmer et al. 2001). IQ scores can predict certain forms of achievement, 
e.g. academic achievement, and subsequently occupational and financial 
outcome, although this correlation only accounts for about 25 % of the 
variance (Strauss et al. 2006). Other individual factors, such as perseverance, 
interest and motivation are probably equally important in academic 
achievement (Neisser et al. 1996).  
Specific cognitive deficits 
The most common specific cognitive deficits reported in childhood brain 
tumor survivors involve attention, memory  especially working memory , 
executive function, processing speed, visual-motor integration and visual-
spatial functioning (Lannering et al. 1990a, Butler and Haser 2006, Edelstein 
et al. 2011, Palmer et al. 2013). Attention can be subdivided in sustained and 
selective attention. Sustained attention is the capacity to maintain focus and 
alertness over time; and selective attention (focused attention) is the ability to 
select target information from an array while ignoring irrelevant stimuli 
(Mirsky et al. 1991). Working memory can be described as a short-term 
memory buffer that allows us to hold information in our mind and mentally 
work with it (Cowan 2008). For example, working memory is used when 
baking a cake, to avoid adding the same ingredient twice, or when solving an 
arithmetic problem in your head. Working memory is also necessary to make 
sense of written or spoken language. When reading a sentence, you need to 
remember the beginning of the sentence when you reach the end of it, (as you 
hopefully just did). Working memory is distinct from short-term memory, 
although some consider working memory to be a part of short-term memory 
(Cowan 2008). The latter only requires the holding of information in mind, 
without manipulation (Diamond 2013). Working memory is generally 
divided in two types, verbal and visual-spatial. 
Long-term memory can be separated into two broad forms: declarative and 
non-declarative (Shohamy and Turk-Browne 2013). Declarative memory 
handles long-term, conscious memories of general facts, including new word 
meanings (semantic memory), and personal events that have a specific 
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context in space and time (episodic memory). Non-declarative memory 
(procedural memory) handles the rest, e.g. nonconscious learning of skills 
and habits, perceptual information, and emotional and motor responses 
(Squire 2004). Declarative memory relies on the medial temporal lobe 
(including the hippocampus), whereas habit learning involves primarily the 
striatum, although there is interaction between these two systems (Knowlton 
et al. 1996). 
Executive function (executive control) is a psychological construct that covers 
the cognitive processes responsible for planning, sequencing, and controlling 
goal-directed behavior (Banich 2009). These processes allow us to make a 
plan, initiate its execution, and persevere on the specific task until its 
completion, but also to quickly adapt to diverse situations as well as inhibit 
prepotent responses (Jurado and Rosselli 2007). Executive functions consist 
of at least three basic functions: shifting (between tasks or mental sets, 
sometimes called cognitive flexibility), updating (of working memory), and 
inhibition (of automatic, or prepotent responses, when necessary) (Miyake et 
al. 2000).  
Processing speed can be described as the rate at which a person can take in a 
bit of new information, reach some judgment on it and then formulate a 
response (Fry and Hale 2000). It has been defined as the general rate at which 
a person can complete cognitive operations, and can be viewed as a measure 
of the efficiency of the system (Kail 2000). As children develop, they process 
information more rapidly, reflecting age-related changes in the CNS, such as 
myelination. 
Academic achievement is directly related to the skills and knowledge children 
acquire at school and is an ecologically valid measure regarding 
psychological outcomes, reflective of their daily functioning (Mabbott et al. 
2005) After radiotherapy treatment, children fall progressively behind their 
peers in academic skills (reading, spelling, and mathematics), due to a 
reduced rate of skill acquisition. Although academic achievement is 
correlated to IQ, the academic decline remains also when adjusting for the 
decline in intelligence, and it is likely that other factors (i.e. fatigue, absence 
from school) contribute (Mabbott et al. 2005). 
1.4.2 Factors associated with cognitive dysfunction 
When survival rates for medulloblastoma began to improve in the 1970s, 
initial reports were also optimistic regarding functional outcomes, with e.g. 
Bloom et al. reporting 82 % of survivors having no or mild disabilities 
(Bloom et al. 1969). However, a number of reports that followed described 
serious cognitive side effects in the survivors (Hirsch et al. 1979, Duffner et 
al. 1983, Silverman et al. 1984). 
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Radiotherapy  
The most important treatment-related factor for cognitive late effects is 
probably cranial radiotherapy, and the negative cognitive impact of 
radiotherapy has been confirmed in multiple studies (Mulhern et al. 1989, 
Mulhern et al. 1992, Palmer et al. 2001, Brinkman et al. 2016). An early 
publication by Duffner et al., reported of 10 children with posterior fossa 
tumors treated with surgery, craniospinal radiation and chemotherapy. All 
children had either mental retardation, or cognitive decline, and/or learning 
disorders, with 40 % having IQs <70 (Duffner et al. 1983). Several 
subsequent studies confirmed these findings, and also found lower age (at 
radiotherapy) to be a risk factor for the most severe cognitive deficits 
(Duffner et al. 1988, Packer et al. 1989, Lannering et al. 1990a, Mulhern et 
al. 1998). It has also been established that the risk of cognitive deficits 
increases with higher radiation dose (Goldwein et al. 1996, Mulhern et al. 
1998, Grill et al. 1999, Kieffer-Renaux et al. 2000, Merchant et al. 2014), 
larger irradiation fields, or combinations of larger doses and fields (Grill et al. 
1999, Kieffer-Renaux et al. 2005, Moxon-Emre et al. 2014).  
Surgery 
The importance of the cerebellum also for non-motor abilities, such as 
language, thought modulation, emotions, and planning, has gained increased 
attention, but the surgical contribution to deficits found after cerebellar tumor 
treatment was for long less known. Several studies have demonstrated that, 
although patients with cerebellar tumors (treated with surgery alone) had 
FSIQ scores within normal range, a majority had partial cognitive deficits 
affecting memory, attention, visual-spatial abilities, and executive function 
(Levisohn et al. 2000, Riva and Giorgi 2000, Steinlin et al. 2003). 
Furthermore, behavioral problems were described in one third of the patients 
(Levisohn et al. 2000, Steinlin et al. 2003). Other studies have found a 
cognitive impact from isolated surgical treatment, both after surgery for 
cerebellar tumors; affecting sustained attention, visual-spatial function, 
executive function, and visual-spatial memory (Aarsen et al. 2004), and for 
tumors in supratentorial locations (Carpentieri et al. 2003). The impact on 
cognition from the tumor itself (discussed below) is difficult to disentangle 
from the surgical impact. Repeated surgery and perioperative complications 
have been associated with lower IQ in medulloblastoma patients (Kao et al. 
1994), and surgical complications, e.g. cerebellar mutism, with lower Verbal 
and Performance IQ in both irradiated and non-irradiated patients (Grill et al. 
2004, Ris et al. 2013).  
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Chemotherapy 
Many studies that evaluated the cognitive effects of multimodal brain tumor 
treatment, found no significant impact on cognition from chemotherapy, at 
least not compared to the impact from radiotherapy (Grill et al. 1999, Palmer 
et al. 2001, Reimers et al. 2003). A medulloblastoma trial for young children 
(< 3 years) used intensive postoperative chemotherapy alone (including 
intraventricular methotrexate, Mtx, but without radiotherapy), and found the 
mean IQ score after treatment to be significantly lower compared to healthy 
controls, but significantly higher compared to children treated with 
radiotherapy, in an earlier trial, (Rutkowski et al. 2005). 
Much of the data on the cognitive effects of chemotherapy alone have come 
from studies of children treated for leukemia (without CNS involvement), 
where fewer confounding variables are involved. In a study of patients 
treated for acute lymphatic leukemia (ALL) with a chemotherapy-only 
protocol, no significant differences were found in the survivors´ IQ, academic 
skills, learning, or memory, compared to normative expectations (Jacola et al. 
2016). However, significantly more children than expected (16 %) performed 
below average in measures of sustained attention, and caregivers reported a 
greater frequency of learning problems (Jacola et al. 2016). A Nordic study 
found progressive deficits in Verbal and Performance IQ in ALL survivors 
treated with cranial irradiation, as well as significantly lower test scores in 
memory functions, attention and motor functions, compared to ALL patients 
treated with chemotherapy only, and to healthy controls (Harila et al. 2009). 
Although the chemotherapy-only treated group performed significantly better 
than the radiotherapy treated group, they had statistically significant 
impairments in VIQ and PIQ, sequential reasoning, working memory and 
information processing speed, compared to controls (Harila et al. 2009). The 
combination of intrathecal (i.t.) Mtx and cranial irradiation has been found to 
be more detrimental for cognition compared to radiotherapy alone (Iuvone et 
al. 2002, Riva et al. 2002, Mitby et al. 2003). The sequence of treatment 
seems to be important, with a more pronounced IQ decline when Mtx is 
given after radiotherapy, rather than before (Balsom et al. 1991). 
Other factors 
Although treatment often is blamed for the cognitive decline after childhood 
brain tumor treatment, several other factors correlate with cognitive outcome. 
Negative risk factors include: lower age at diagnosis (Mulhern et al. 2001), 
female sex (Mulhern et al. 2004b, Merchant et al. 2014), hydrocephalus 
(Merchant et al. 2004, Moxon-Emre et al. 2014, Brinkman et al. 2016), 
seizures/epilepsy (Iuvone et al. 2011, Brinkman et al. 2016), and neurologic 
complications (Moxon-Emre et al. 2014). 
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One must not forget the child´s pre-morbid abilities, but also the impact from 
the brain tumor itself. Several studies have found cognitive difficulties 
already at diagnosis (before treatment), in up to 50 % of patients, compared 
to norm (Iuvone et al. 2011). Comparing to norms could however be 
problematic, since some impairment could be due to the stressful situation, 
and the test results negatively affected by anxiety and physical discomfort. In 
an attempt to control for this, Margelisch and co-workers compared newly 
diagnosed pediatric brain tumor patients to children with an oncological 
diagnosis not involving the CNS, and found significantly impaired cognitive 
abilities in the brain tumor patients, involving working memory, verbal 
memory and attention (but no difference in perceptual reasoning, processing 
speed, or verbal comprehension) (Margelisch et al. 2015). Other tumor 
related factors include the location of the tumor (Iuvone et al. 2011), tumor 
size (Tonning Olsson et al. 2014), and medulloblastoma subgroup (Moxon-
Emre et al. 2016).  
To conclude, the cognitive impairment after treatment is most certainly 
caused by multiple factors, including host factors, tumor, treatment, and other 
factors.  
1.4.3 Neurogenesis in the brain 
Throughout life, human neurogenesis occurs in the brain, mainly in the 
dentate gyrus of the hippocampus and the lateral wall of the lateral ventricles, 
in the subventricular zone (SVZ) (Eriksson et al. 1998). The SVZ is the 
subependymal cell layer that lies directly subjacent to the ventricular 
ependyma. These areas contain neural stem and precursor cells, collectively 
known as neural progenitor cells (NPCs).  
Hippocampus 
In the dentate gyrus of the hippocampus, NPCs in the subgranular zone 
(SGZ) generate granule cells, which migrate into the granule cell layer (GCL) 
where they integrate into neural circuits and become functional neurons (van 
Praag et al. 2002). Many neurons fail to integrate, and subsequently die (Zhao 
et al. 2008). Hippocampal neurogenesis appears to be involved in memory 
formation (Shors et al. 2001), and hippocampus-dependent learning leads to 
increased hippocampal neurogenesis, at least in animal models (Gould et al. 
1999, van Praag et al. 1999, Curlik and Shors 2011). Furthermore, selective 
inhibition of hippocampal neurogenesis leads to impairments in spatial 
memory tasks (Deng et al. 2009). 
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The hippocampus is important in declarative memory, something that was 
discovered by accident in 1953. After bilateral medial temporal lobe 
resections (due to intractable seizures), the patient H.M. experienced 
permanent severe anterograde amnesia (Scoville and Milner 1957). The 
amnesia manifested itself as a permanent disability in forming new episodic 
and semantic memories, and much knowledge has come from the study of 
this single patient (Corkin 2002). The hippocampus does not store memories, 
but rather processes and prepares incoming information before sending it 
back for long-term storage in the neocortex.  
The hippocampus also has a role in other cognitive functions, beyond 
declarative memory. It has been described as a bridge between perception 
and decision making, implicated in imaging the future, keeping track of space 
and time, perception and attention as well as reward (Shohamy and Turk-
Browne 2013). The hippocampus is important for the processing of spatial 
layouts, topographical memory, and navigation (O'Keefe and Nadel 1978, 
Maguire et al. 1997). An indication of this was demonstrated by the posterior 
hippocampi of London taxi drivers being significantly larger than those of 
controls, and that posterior hippocampal volume correlated positively with 
the number of years spent as a taxi driver (Maguire et al. 1997, Maguire et al. 
2000). It is also implicated in social navigation, helping to keep track of 
memories of social interactions through a “social map” (Tavares et al. 2015). 
Subventricular zone 
Neurogenesis in the SVZ has a less clear role, at least in humans. In rodents, 
quiescent radial glia-like cells (B-cells) become activated and give rise to fast 
dividing transient amplifying cells (C-cells), which in turn generate 
neuroblasts (A-cells), which migrate through the rostral migratory stream 
(RMS) to the olfactory bulb, where they end up as interneurons (Doetsch et 
al. 1999a, Ming and Song 2011). Although this appears to occur also in 
humans (Curtis et al. 2007, Wang et al. 2011), the extent of this migration 
seems to be much smaller or even minimal compared to rodents, at least after 
the perinatal period (Wang et al. 2011, Bergmann et al. 2012). In humans, 
instead of supplying neurons to the olfactory bulb, evidence suggests that 
adult neurogenesis in the SVZ produces neurons ending up as interneurons in 
the striatum (Ernst et al. 2014). Apart from neurons, type B cells also give 
rise to oligodendrocytes and astrocytes (Chaker et al. 2016). Interestingly, 
SVZ neurogenesis seems to have a role also in brain repair e.g. in ischemia 
(Arvidsson et al. 2002, Jin et al. 2006, Osman et al. 2016), and for providing 
remyelinating oligodendrocytes in models of demyelinating disease (Xing et 
al. 2014). 
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Several of the studies (e.g. Bergmann et al. 2012, Ernst et al. 2014), proving 
(or disproving) post-natal neurogenesis in different areas of the human brain 
have relied on a ground-breaking birth-dating method that uses carbon-14 
(14C), generated by the cold war atomic bomb tests, to date neurons in human 
brain tissue (Spalding et al. 2005). Using this method, it was determined that 
cortical neurons are as old as the individual, and that neurons in the cortex are 
not replaced by postnatal neurogenesis (Spalding et al. 2005, Bhardwaj et al. 
2006). In the cerebellum, the average age of neurons were found to be 2.9 
years (after the individual´s birth), indicating neuronal cell proliferation 
destined for the cerebellum during the first post-natal years (Spalding et al. 
2005).  
1.4.4 Damaging mechanisms from radiotherapy 
Radiobiology 
The exact mechanisms of cell death due to ionizing radiation is still an area 
of active investigation, but the most important mechanism is through DNA 
damage. Radiation ionizes cell molecules either directly, or indirectly via 
free-radical intermediates formed from the radiolysis of water. The direct 
energy, or energy released by these free radicals, break the phosphodiester 
bonds in the backbone of the DNA helix and cause single- or double-strand 
breaks. Alterations of the DNA bases and crosslinks between DNA strands 
and chromosomal proteins are important reactions as well. Cells respond to 
DNA damage by inducing cell-cycle arrest to allow repair. If repair is 
unsuccessful or the damage is severe, it results in permanent cell cycle arrest, 
p53-mediated apoptosis, or mitotic catastrophe (Gudkov and Komarova 
2003). Highly proliferating cells tend to enter apoptosis, whereas low-
proliferating cells (e.g. fibroblasts) tend to enter growth arrest (Gudkov and 
Komarova 2003). Damaging reactions with cell membranes in e.g. 
endothelial cells and oligodendrocytes can also trigger apoptosis 
mechanisms, via sphingomyelinase-mediated release of ceramide (Kolesnick 
and Fuks 2003). Furthermore, irradiation causes sustained elevations of 
reactive oxygen species (ROS) in cells and tissues, leading to a shift in the 
redox homeostasis, which could alter the course of cell proliferation, cell 
differentiation, and affect long-term cell survival (Limoli et al. 2004). 
Irradiation is damaging to neurogenesis  
Animal studies have shown that when brains of young rodents are irradiated, 
the volume of the irradiated hippocampus is reduced corresponding to an 
apoptosis-induced loss of proliferating neural stem and progenitor cells, 
rendering the tissue incapable of normal growth (Monje et al. 2002, Fukuda 
et al. 2004, Rola et al. 2004). The reduction in neurogenesis leads to a 
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profound reduction in newborn neurons, whereas the production of newborn 
astrocytes or oligodendrocytes is relatively spared (Monje et al. 2002). The 
damage to the neurogenic regions is greater in younger animals and it is also 
sustained, at least until the animals become adult (Hellström et al. 2009). The 
reduced neurogenesis is not merely a function of reduced NPC numbers or 
proliferative activity, but also due to inhibitory alterations of the neurogenic 
microenvironment (Monje et al. 2002). One hypothesis is that chronic 
inflammation after radiotherapy influences NPC proliferation as well as cell 
fate. Radiation-induced inflammation has been demonstrated to cause 
neuronal progenitors to differentiate into glial cells instead of neurons, and an 
increase in microglia (Monje et al. 2002). In the juvenile brain neurogenesis 
is even more sensitive to irradiation, but there seem to be differences in the 
inflammatory response to irradiation compared to the adult brain (Blomstrand 
et al. 2014). 
In contrast to the profound and long-lasting effect of irradiation, 
intraventricular infusion of the chemotherapeutic drug Ara-C (cytarabine) 
severely reduced the number of fast-dividing precursors/neuroblasts in the 
SVZ, but the effect was transient and the cell population was normalized 
within a week (Doetsch et al. 1999b, Ahn and Joyner 2005). Another study 
however, found a more long lasting detrimental effect on in vivo 
neurogenesis after treatment with BCNU or cisplatin, lasting at least six 
weeks (Dietrich et al. 2006). 
Disrupting hippocampal neurogenesis causes decreased performance in 
hippocampal-dependent memory tasks and behavioral tests in rodents (Rola 
et al. 2004, Barlind et al. 2010, Karlsson et al. 2011). A study in humans 
treated with chemotherapy and cranial irradiation showed profoundly reduced 
hippocampal neurogenesis in combination with reported memory deficits, 
supporting the hypothesis that neurocognitive impairment after CNS-directed 
therapy to some degree is due to a hampered hippocampal neurogenesis 
(Monje et al. 2007). In a study correlating radiation doses to different brain 
regions with cognitive outcome, a higher radiation dose to the (right) 
hippocampus was associated with reduced reading scores (Merchant et al. 
2014). 
Irradiation is damaging to white matter and blood vessels 
Radiation affects oligodendrocytes, and together with vascular changes, this 
probably contributes to white matter damage (Mulhern et al. 1999). White 
matter damage, (i.e. a reduction of normal appearing white matter or reduced 
white matter integrity on MRI), can be seen after radiotherapy, and correlates 
to cognitive deficits, i.e. a decrease in IQ, (Mulhern et al. 1999, Palmer et al. 
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2001) working memory (Jacola et al. 2014), and executive function 
(Brinkman et al. 2012). In the study by Mulhern et al. (1999), surgery alone 
did not affect the amount of normal appearing white matter. Furthermore, 
neither the addition of chemotherapy to radiotherapy, nor (surprisingly) 
treatment with a higher radiotherapy dose, decreased the amount further 
(Mulhern et al. 1999). Younger age at radiotherapy has been associated with 
less normal appearing white matter (Mulhern et al. 2001). It is possible that 
the white matter is more sensitive to irradiation during the rapid myelination 
that occurs in children and adolescents (Moore 2005). A specific form of 
MRI abnormality, cerebral microbleeds, has been observed on MRIs after 
radiotherapy. In a retrospective MRI study, cerebral microbleeds were 
associated with previous cranial radiation (and chemotherapy) (Roddy et al. 
2016). A high number of microbleeds correlated with worse cognitive 
function (Roddy et al. 2016), but the contribution of these microbleeds to the 
cognitive decline is at present unclear. In the hippocampus, the reduction in 
proliferating cell numbers has been attributed to a direct effect on NPCs 
rather than blood vessels (Boström et al. 2013). 
1.4.5 Means to mitigate the cognitive side effects 
Prevention 
Avoiding radiotherapy by substituting it for chemotherapy has for long been 
the only strategy available, and is still used especially in the more 
radiosensitive younger children (Rutkowski et al. 2005, Lafay-Cousin et al. 
2009). With Proton beam therapy, a better delineation of the radiation field is 
possible, and irradiation of the hippocampi could thereby be avoided. This 
could potentially reduce the cognitive side effects, although it remains to be 
tested in a pediatric clinical trial (Blomstrand et al. 2012, Brodin et al. 2014). 
A study of hippocampal avoidance in whole brain radiotherapy in adults 
found significant (verbal) memory preservation compared to historical 
controls (Gondi et al. 2014). Also with conventional modern photon 
radiation, a reduction of the radiation field can improve cognitive outcome. In 
medulloblastoma treatment, the radiation boost field is nowadays restricted to 
the tumor bed (and not the entire posterior fossa), with positive effects on 
cognition (Moxon-Emre et al. 2014). As discussed previously, a lower 
radiation dose to the brain also reduces the cognitive late effects. 
Hypothermia 
Hypothermia is used in clinical pediatric practice to treat newborn infants 
with hypoxic-ischemic encephalopathy, and has in randomized controlled 
trials been reported to improve both neurological outcome and survival 
(Azzopardi et al. 2009, Jacobs et al. 2013). In hypoxic-ischemic 
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encephalopathy, post-insult hypothermia is neuroprotective through several 
different mechanisms that are also relevant after irradiation, including anti-
apoptosis, anti-inflammation, and anti-oxidative mechanisms (Ma et al. 
2012). Hypothermia has not been studied in children receiving radiotherapy. 
A previous rodent study indicated a possible protective effect on the 
neurogenic regions of the brain after irradiation, and inspired the study 
presented in Paper IV. Hyperthermia on the other hand, had detrimental 
effects on neurogenesis (Fukuda et al. 2005).  
Cognitive training 
In a small study by van´t Hooft and co-workers, children with acquired brain 
injury (including brain tumor patients) were randomized to regular cognitive 
(and metacognitive) training (daily 30-minute exercises in specific attention 
and memory techniques with a coach), vs control (doing a freely chosen daily 
interactive activity for 30 minutes). After a 17-week intervention, positive 
effects were found in measures of sustained and selective attention, as well as 
memory performance (van’t Hooft et al. 2005, van’t Hooft et al. 2007).  
A larger randomized multi-center study examined the effects of a cognitive 
remediation program (20 two-hour sessions over 4-5 months), including 
cognitive and metacognitive training, on brain-irradiated childhood cancer 
patients and found a modest positive effect on academic achievement and 
parent-reported attention, but not in tests of selective attention, working 
memory or vigilance (Butler et al. 2008). A drawback was the substantial 
time commitment needed from all involved, with only 60% of participants in 
the intervention arm completing the entire program. 
Computerized cognitive training 
In a randomized, single-blind, waiting list controlled study, Conklin and 
coworkers evaluated a computerized intervention using Cogmed 
(http://www.cogmed.com), in 8-16 years old survivors of ALL (n=47) and 
childhood brain tumors (n=21) (Conklin et al. 2015). Cogmed is a 
computerized game-like intervention, where repetitive visual–spatial and 
verbal working memory exercises of graded difficulty are used. The 
intervention period consisted of 25 home-based sessions (30-45 min each), 
over 5 to 9 weeks, with weekly telephone-based coaching. Improvements 
from pre- to post-intervention tests were seen in measures of working 
memory, attention, processing speed and executive function, but not in 
academic fluency. (Conklin et al. 2015). Compliance was good at 88 %.  
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Video gaming 
A large number of studies have reported improvements in various aspects of 
cognition from ordinary video (computer) gaming, including improvements 
in attention, information processing, task switching flexibility and visual 
processing (Powers et al. 2013). A cross-sectional study of video gaming 
showed that young adults who played computer games had better spatial and 
temporal visual attention, as well as increased visual attention capacity, 
compared to non-gamers (Green and Bavelier 2003). Furthermore, the non-
gamers improved their visual attention capacity after training action video 
games for just 10 days, compared to a control group playing slower paced 
video games (Tetris) (Green and Bavelier 2003).  
A longitudinal study in adults examined structural changes in the brain after 2 
months of daily video gaming. (Kuhn et al. 2014). In this MRI-study, grey 
matter volume changes were observed between pre- and post-test and 
between experimental and control group, in the right hippocampus and right 
dorsolateral prefrontal cortex. Interestingly, a game with a prominent 
navigation component was used, and the cortical areas affected are thought to 
be involved in navigation. Changes were also seen in the cerebellum. 
Cognitive testing was however, not performed. (Kuhn et al. 2014). Another 
study compared different types of games and found that children playing 
action video games had shorter reaction times (without making more errors), 
compared to those playing non-action video games, and the authors 
concluded that action video gamers had enhanced attentional resources (Dye 
et al. 2009). There is however, some debate as to whether improvements seen 
are a result of bias due to study design flaws (e.g. differential recruitment bias 
in cross-sectional studies), or differential placebo effects, and also if the 
improvements are transferable to other tasks (Boot et al. 2008, Boot et al. 
2011). Concerns also persist about whether video games foster aggression or 
addictive play (Calvert et al. 2017). 
Active video gaming (exergaming)  
In a Dutch study, children and young adults with acquired brain damage 
exercised using active video gaming (Nintendo Wii), for two hours per week 
for 12 weeks. Test results before and after were compared, and showed 
improvements in processing speed, attention, and response inhibition tests 
(de Kloet et al. 2012). A study of the effects of a single bout of physical 
activity studied different combinations of physical activity and cognitive 
engagement, and compared active video gaming to sedentary video gaming 
or watching a video (Best 2012). The physical activity level was found 
important for improving executive function, but with no added effect from 
increasing the cognitive engagement level (Best 2012). The authors 
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speculated however, that the activity chosen to deliver high physical activity 
but low cognitive engagement, could have been more cognitively demanding 
than intended. This speculation might be true, since a similar study found a 
significant improvement in executive function (cognitive flexibility) from 
cognitively engaging physical activity, compared to simple aerobic activity or 
control (Benzing et al. 2016). It should be noted that both studies examined 
the acute effects of exercise, and not the effects of long-term physical 
activity. 
Physical activity 
A positive correlation of physical exercise with better cognitive function, 
including executive function and memory, has been demonstrated in multiple 
studies, in both children and the elderly (Barnes et al. 2003, Colcombe et al. 
2004, Etnier et al. 2006, Erickson et al. 2011). Some studies provide 
correlative evidence, others are cross-sectional studies and some are 
randomized intervention trials. A large cohort study on young adult men 
found a positive association between cardiovascular fitness and IQ, even after 
adjusting for relevant confounders (Åberg et al. 2009). A meta-analysis of 
randomized controlled trials in adults found aerobic exercise to be associated 
with modest improvements in attention, processing speed, executive function 
and memory, but not in working memory (Smith et al. 2010).  
A study of pediatric brain tumor survivors investigated the relationship 
between cardiorespiratory fitness and executive functioning, and found a 
correlation between higher cardiovascular fitness and a more efficient brain 
activation pattern (measured with fMRI) during a working memory task 
(Wolfe et al. 2012). In a randomized study involving pediatric brain tumor 
survivors previously treated with radiotherapy, Riggs and coworkers found 
that aerobic exercise, (three 90-minute sessions per week for 12 consecutive 
weeks) increased the hippocampal volume, and specific white matter tracts 
(i.e. corpus callosum and cingulate gyrus) and decreased reaction times on 
tasks of attention, processing speed, and short-term memory (Riggs et al. 
2016). Apart from the study presented in this thesis (Paper II and III), this is 
so far the only intervention study that has examined the effect of physical 
activity on cognition in pediatric brain tumor patients. However, several other 
studies have investigated the cognitive effects of physical activity in other 
pediatric populations.  
In a study by Davis et al., sedentary overweight 7-11 year-olds (n=171) were 
randomized to a daily exercise program (20 or 40 min/day), or to a control 
group, for a duration of three months. A dose-response benefit from exercise 
on executive function (planning) and mathematical academic achievement 
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was found, but not in reading or attention (Davis et al. 2011). Schmidt and 
coworkers explored the impact of cognitive engagement during physical 
activity on cognitive outcome, by randomizing 10 to 12-year-olds to one of 
three different interventions. Group one performed team games with sudden 
rules changes (i.e. high level of physical activity + high level of cognitive 
engagement), group two did aerobic exercise (high level of physical activity 
+ low level of cognitive engagement), and group three did a control activity 
(with low level of both physical activity and cognitive engagement) (Schmidt 
et al. 2015). The intervention lasted for six weeks with two exercise sessions 
per week. Interestingly, although the two high-level physical activities 
reached the same level of physical exertion, the team game group had a 
stronger improvement in certain aspects of executive function (shifting) but 
not in others (updating and inhibition), compared to the other two groups 
(Schmidt et al. 2015). A similar study in younger children (5-9 years old), 
also found a larger improvement in executive function (attention) when using 
a more cognitively challenging form of physical activity (Pesce et al. 2013).  
A 9-year long intervention study randomized school children to either daily 
physical exercise in school (225 min/week, plus one hour per week of motor 
skills training to pupils with specific needs), or two days per week (90 
min/week), and found a reduction in motor skills deficits from 47 % to 7 % 
and an increased proportion of pupils who qualified for upper secondary 
school, in the group with more physical education (Ericsson and Karlsson 
2014). In a randomized controlled trial, 24 elementary schools were 
randomized to physical activity across the curriculum (PAAC) or control 
(Donnelly et al. 2009). The aim was to study the effect of exercise on body 
mass index (BMI), but as a secondary outcome academic achievement was 
also measured. The intervention consisted of 10-minute sessions of moderate 
to vigorous physical activity delivered intermittently throughout the school 
day (90 minutes per week) over three years. They found improved academic 
results in schools randomized to PAAC, but no effect on BMI (Donnelly et 
al. 2009). A randomized, primary school-based, pilot trial with healthy 
children, randomized between two hours per week of aerobically intense 
physical education vs normal physical education, and found significant 
improvements in tests for attention and working memory, but not for 
executive function (Fisher et al. 2011). 
In a cross-sectional study comparing higher-fit with lower-fit children (8-10 
years), the higher-fit children outperformed their lower-fit peers on a 
simulated real-world task: street crossing. Interestingly, the fitter children 
were not quicker at crossing streets than the less-fit children, but were less 
susceptible to distraction and made better decisions about when to cross 
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(Chaddock et al. 2011). In the Fitness Improves Thinking in Kids (FITKids) 
trial, 221 children (7-9 years old) were randomized to a 9-month after-school 
exercise program (for two hours each school day) or a waiting list control 
group (Hillman et al. 2014). Compared to the control group, the exercise 
group improved significantly in aerobic fitness, response accuracy, and 
cognitive flexibility, but not in reaction time. Improvements measured by 
neurophysiological changes (event-related brain potentials derived from 
EEGs) were also reported (Hillman et al. 2014). 
Regarding the effects of physical activity on executive function, the majority 
of studies have been performed in the elderly, and fewer in children, 
adolescents and young adults (Verburgh et al. 2014). A meta-analysis of the 
effects of acute and chronic physical activity (chronic defined as 6-30 weeks) 
on executive function in children, adolescents and young adults, found a 
positive effect from acute exercise, but failed to find a significant overall 
effect from chronic exercise (Verburgh et al. 2014). However, only five (out 
of 24) studies evaluated chronic effects, and the authors concluded that more 
studies on the chronic effects of exercise were needed (Verburgh et al. 2014). 
Pharmacological treatment 
Methylphenidate is believed to enhance the function of the fronto-striatal 
attentional network, and is probably the most studied medication in pediatric 
attention deficit disorder (ADD) (Castellino et al. 2014). In children with 
ADD, methylphenidate can improve measures of vigilance, sustained 
attention, and reaction time (Chavez et al. 2009). There are a few studies of 
methylphenidate in children with brain tumors. Three of them have examined 
partly the same patient population: In a short-term (three weeks), 
randomized, double-blind, crossover trial, 40 ALL and 43 brain tumor 
patients received either placebo or methylphenidate in a low or moderate 
dose (0.3 or 0.6 mg/kg). Parents and teachers reported improvements in 
behavioral rating scores, and teachers (but not parents) reported 
improvements in social rating scores. Academic achievement was not 
evaluated (Mulhern et al. 2004a).  
Before study entry in the three-week trial, potential patients had to 
demonstrate adequate medication tolerance in a separate 2-day, single-dose, 
double-blind, randomized, crossover trial between methylphenidate and 
placebo (Conklin et al. 2007). The 2-day trial included 122 children (61 brain 
tumor patients), and demonstrated improvement after methylphenidate in 
Stroop Word-Color Association Test (a measure of attention, cognitive 
flexibility, and processing speed) (Conklin et al. 2007). After completing the 
three-week trial, patients could enter a 12-month open-label trial (Conklin et 
Brain tumors in children 
34 
al. 2010). In this trial the control group (n=54) was recruited from cancer 
survivors that had been screened and found eligible for the previous trials, but 
either had declined participation in any medication phase, or had participated 
but discontinued the medication, or had been classified as non-responders 
(Conklin et al. 2010). Sixty-eight children and adolescents (6-18 years, 35 
with malignant brain tumors, 33 with ALL) completed the 12-month 
treatment. The methylphenidate treated group demonstrated an improved 
performance in sustained attention, as well as on parent, teacher and self-
report measures of attention, and also on parent report of behavior problems 
and social competencies. However, controls also showed improvements on 
parent report measures of attention, behavior problems, and social 
competencies. Neither group improved in IQ or academic skills (Conklin et 
al. 2010). A substantial rate of study termination due to medication side 
effects among brain tumor survivors has been reported, suggesting an 
increased vulnerability with methylphenidate in this patient population 
(Conklin et al. 2009).  
A small, open-label, pilot study evaluated the feasibility, tolerance, and 
cognitive impact of the acetylcholinesterase inhibitor donepezil, in previously 
irradiated pediatric brain tumor patients, and reported improvements in tests 
of executive function and visual memory (Castellino et al. 2012).  
Ecological 
Last but not least, the child´s environment, especially in school, needs special 
attention in order to facilitate rehabilitation and learning. Since academic 
problems can appear soon after diagnosis, it is important that pedagogic 
interventions are instituted early after diagnosis (Mulhern and Butler 2004). 
1.4.6 Effects of physical activity on cognition, 
potential mechanisms 
Physical activity has several different effects on the brain, and the resulting 
positive effects on cognition are probably multifactorial. Enhanced 
hippocampal neurogenesis is one of the most reproducible effects of exercise 
in the rodent brain, resulting in improved learning in younger as well as older 
mice (van Praag 1999, van Praag 2005, Fabel et al. 2009). A running study in 
brain-irradiated mice, by Naylor et al., was the inspiration for the clinical 
study presented in Paper II and III (Naylor et al. 2008). It was found that 
voluntary running after brain irradiation improved hippocampal 
neurogenesis, with better neuronal integration of new neurons in the dentate 
gyrus, compared to a group of non-running mice (Naylor et al. 2008). The 
running mice also showed a more normal behavior compared to non-runners.  
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Running has been shown to increase the levels of neurotrophins (e.g. brain-
derived neurotrophic factor, BDNF) in the hippocampus (Neeper et al. 1995), 
and also improve hippocampal blood perfusion (van Praag 2005). By using 
MRI-methods, an increase in cerebral blood flow in the dentate gyrus was 
demonstrated in humans within two weeks after exercise, seemingly 
corresponding to an exercise-induced increase in neurogenesis (Pereira et al. 
2007). MRI measurements have also shown an increase in hippocampal size 
after 12 months of aerobic exercise training, in a randomized trial (walking vs 
stretching), involving older adults (Erickson et al. 2011). Cross-sectional 
MRI studies of children and adolescents have found some brain regions to be 
larger in higher-fit children compared to lower-fit children (Chaddock et al. 
2010a, Chaddock et al. 2010b). These brain regions, the hippocampus and the 
striatum, are known to be important for declarative learning and habit 
learning and have been suggested to play a role in learning while 
multitasking (Foerde et al. 2006). In the previously mentioned study by Riggs 
et al., hippocampal size was normalized after exercise, in previously brain-
irradiated children (Riggs et al. 2016). 
Physical activity seems to improve long-term potentiation (i.e. give a 
persistent increase in synaptic strength between two neurons), and improve 
synaptic plasticity (Farmer et al. 2004). Evidence points to a positive effect 
on white matter structure from physical activity (Chaddock-Heyman et al. 
2014, Riggs et al. 2016). Physical activity resulted in an increased efficiency 
of cognitive control networks in children, according to a cross-sectional study 
(Voss et al. 2011), a finding that was confirmed in a randomized longitudinal 
trial (Chaddock-Heyman et al. 2013). Furthermore, the combination of 
physical activity and cognitively challenging tasks (enriched environment) 
seems to have additive effects on hippocampal neurogenesis (Fabel et al. 
2009). 
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2 AIMS 
The overall aims of this thesis were twofold;  
1) To describe and analyze relapses after treatment for standard risk 
medulloblastoma, aiming to find potentially successful treatments and to 
analyze the impact of clinical and biological factors on prognosis after 
relapse. 
2) To explore ways to lessen the side effects of pediatric brain tumor 
treatment, especially the cognitive side effects. 
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3 PAPER I (MEDULLOBLASTOMA 
RELAPSE STUDY) 
3.1 Specific aims for Paper I  
The aims for Paper I were to:  
1) Estimate the long term survival after treatment for standard 
risk medulloblastoma, in the HIT-SIOP PNET4 cohort. 
 
2) Acquire detailed information on medulloblastoma relapse 
(diagnosis, site, and timing of relapse), relapse treatment and 
outcome after relapse in this cohort. 
3.2 Materials and methods (Paper I) 
In Paper I, all 338 patients in the randomized HIT-SIOP PNET4 trial 
(described above) were included and data collected on survival, as well as 
detailed information on all relapses and second malignant neoplasms 
(SMNs). Time of relapse was defined as the date of the MRI confirming the 
relapse. Central review of the MRI at relapse was performed in Germany, but 
in all other countries relapse was diagnosed at the treating centers. Detailed 
information on relapse site, reason for performing the MRI, and symptoms 
preceding relapse diagnosis was collected, as well as information on the 
treatment of relapses, intention of treatment (curative or palliative) and the 
date of death. Central review of tumor material was performed at the time of 
primary diagnosis. In addition, a series of molecular biomarkers (β-catenin 
nuclear accumulation, CTNNB1 exon 3 mutation, MYC and MYCN, 
Chromosome 17 alterations) were analyzed as part of the HIT-SIOP PNET4 
study. (For further details see Paper I.) The study was approved by each 
national/institutional review board and all patients/parents/guardians had 
consented to participate. 
3.2.1 Statistical methods 
The probability of EFS and OS after relapse were estimated using the 
Kaplan–Meier method and differences in outcome between patients groups 
were tested using the Log Rank method. Relapse, SMN, death in remission, 
and death after relapse were defined as events. Comparisons of patient 
characteristics between subgroups were performed using Fisher’s exact test, 
Chi square test or ANOVA where appropriate. Prognostic factors after 
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relapse were evaluated by using the Cox multivariate, proportional regression 
analysis. The significance level was set to p=0.05.  
3.3 Results (Paper I) 
Of the 338 patients in the HIT-SIOP PNET4 trial, 76 % were still in CCR1 
when the database was frozen. The fate of the remaining patients is illustrated 
in figure 2. The 72 relapses were studied in detail. 
Figure 2. The fate of patients included in the HIT-SIOP PNET4 trial. Adapted from Paper I 
 
3.3.1 Survival after primary treatment  
When the database was frozen, the patients in the HIT-SIOP PNET4 trial had 
been followed for a median 7.8 years after primary diagnosis. The 10-year 
probability of EFS and OS was 76 % and 78 % respectively. There was no 
difference in 10-year EFS between the two randomization arms (Figure 3).  
3.3.2 Diagnosis of relapse 
Diagnosis of relapse was made by craniospinal MRI in all 72 cases, with 
central review performed in 29/72 (40 %) of cases. Information on the reason 
for performing the MRI was available in 65 cases (90 %). In 45 patients (69 
%), the relapse was diagnosed on surveillance MRI in an asymptomatic 
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patient. In the remaining 20 patients the MRI was preformed due to 
symptoms. No correlation was found between relapse diagnosis (surveillance 
MRI or symptoms) and histological variant, relapse pattern/site, or biological 
factors (MYC/MYCN, chr17 alterations, or β-catenin status). There was a 
trend for β-catenin nuclear positive relapses more commonly being diagnosed 
due to symptoms, compared to non-β-catenin positive tumors (p=0.090, 
Fisher´s exact test). About a quarter of recurrent tumors (17/72, 24 %), were 
histologically verified by biopsy or surgery. 
Figure 3. Probability of event-free survival (EFS) in the two randomization arms of the HIT-
SIOP PNET4 trial. STRT= standard radiotherapy, HFRT=hyperfractionated radiotherapy. 
From Sabel et al. 2016, Paper I 
 
3.3.3 Relapse site and timing of relapse 
The majority of relapses 59/72 (82 %) were metastatic (all within the CNS), 
with or without involvement of the posterior fossa. Most metastatic relapses 
(47/59, 80 %) were multifocal, including cases with leptomeningeal 
dissemination. The remaining 12 metastatic cases were solitary metastases in 
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the brain (n=5) or spine (n=7). Thirteen patients (18 %) had an isolated local 
recurrence in the posterior fossa. In eighteen cases, recurrences were 
confined exclusively to the spine, without cranial manifestations. The 
majority (12/18, 67 %) of isolated spinal relapses were diagnosed by 
surveillance MRI, the remainder due to symptoms. Eight of the 18 MRIs (44 
%) displaying an isolated spinal recurrence were centrally reviewed. 
Information on CSF cytology was known in 61/72 relapses (85 %), with 
malignant cells in 21 cases (34 %). All CSF-positive cases also had tumor 
manifestations visible on MRI.  
The 72 relapses occurred at a mean/median of 30/26 months (range 2 to 95 
months), from diagnosis. Six patients (8 %) had late recurrences, (>5 years 
from primary diagnosis), with one relapse occurring almost eight years after 
primary diagnosis. The majority of late recurrences, 5/6, were isolated 
relapses in PF (n=3) or spine (n=2). Regarding the anatomical distribution of 
early/late recurrences there was a trend for more isolated PF recurrences 
among the late relapses (p=0.07, Fisher’s exact test). When comparing the 
randomization arms, there was no difference regarding the timing of relapses 
or relapse sites. The number of chemotherapy courses received in primary 
treatment (≤ 4 compared to >4) had no impact on the frequency of relapses 
(p=0.398, Fisher’s exact test). 
3.3.4 Relapse in relation to histology and biology 
At primary diagnosis, the tumors were classified as classic MB in 57 cases, 
DMB in 10, and LCA in five cases. There was no relation between 
histological subgroup and time in CCR1, localization of relapse, or survival 
after relapse. Some biological markers could be analyzed: β-catenin status by 
immunohistochemistry (IHC) was known in 80 % of tumors, with a nuclear 
positive pattern in 14 % of these. Nuclear β-catenin positive status had no 
impact on time in CCR1, localization, or survival after relapse. Of the eight 
nuclear β-catenin positive tumors that relapsed, four had other unfavorable 
risk factors, (such as age >16 years, delayed start of radiotherapy and/or 
residual primary tumor >1.5 cm2). The status of Chr 17(im)/diploid 
background could be analyzed in 44 % (positive finding in 31 % of these), 
but was not found to be related to time in CCR1, localization, or survival 
after relapse. MYC/MYCN status was known in 33/72 (46 %) of cases, with 
only 3/33 MYCN amplified cases found (no MYC amplified).  
3.3.5 Second malignant neoplasms 
Three SMNs were reported as primary events. One patient had an anaplastic 
astrocytoma in the pons, one had a glioblastoma in the PF, and one patient 
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(with Li-Fraumeni syndrome) had a rhabdoid tumor in the abdomen. The 
SMNs occurred 61, 55 and 35 months after primary diagnosis, and all three 
patients died.  
3.3.6 Relapse treatment 
Data on treatment of the recurrent tumor was known in 71/72 cases. All but 
four patients received treatment for relapse. Conventional chemotherapy was 
used in the majority of relapses. Surgery was performed in 25 %, 
radiotherapy in 22 %, and HDSCR in 21 % of relapsed patients. Surgery was 
used more often in isolated PF relapses, but gross total resection was 
achieved in less than half of the procedures. HDSCR was also more 
commonly used in isolated PF relapses. Focal re-irradiation (20-45 Gy) was 
used to treat metastases located in the spine, supratentorial metastases or 
relapses in the PF. No patient was re-irradiated with CSI. Data on the use of 
intrathecal chemotherapy was available in 66/72 patients. Seventeen (26 %) 
received intrathecal chemotherapy. Of those with malignant cells in CSF 
(data known in 53/72), 9/21 (43 %) received intrathecal treatment. Five out of 
32 without malignant cells in the CSF also received intrathecal therapy.  
3.3.7 Survival after relapse  
The 3- and 5-year OS after relapse was 20 % and 6 % respectively (Figure 4). 
The patients presenting with symptoms had a significantly shorter survival 
after relapse than those detected by surveillance MRI (median survival 12 
months vs 19 months, p< 0.01), but the OS (after primary diagnosis) did not 
differ (p= 0.21, Log Rank test). An isolated local relapse, (i.e. in the posterior 
fossa), was associated with longer survival compared to all other relapse 
patterns (p= 0.02, figure 5). In Cox multivariate analysis, isolated posterior 
fossa relapse was associated with longer survival (p< 0.01), together with 
surgery (p< 0.01), but not treatment with RT (p= 0.10) or HDSCR (p= 0.44). 
When the data base was frozen, nine patients were still alive. The mean and 
median survival after relapse was 23 and 18 months respectively. 
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Figure 4. Probability of survival (OS) after relapse. From Paper I 
 
Figure 5. Probability of survival after relapse in isolated posterior (PF) relapses and 
craniospinal ± PF relapses. From Paper I  
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3.4 Discussion (Paper I)  
Survival after standard risk medulloblastoma 
The majority of children diagnosed with standard risk medulloblastoma in the 
HIT-SIOP PNET4 trial are survivors, with 10-year EFS and OS around 80 %. 
Survival did not differ between treatment arms (STRT and HFRT), after a 
median follow up of 7.8 years. These results are comparable to the Children’s 
Oncology Group (COG) A9961 study, another large randomized standard 
risk medulloblastoma trial, that reported a 10-year OS of 81.3 % which is 
very similar to the adjusted OS of 81 % in HIT-SIOP PNET4 (Packer et al. 
2012). In both these studies, patients who were not optimally staged at 
primary diagnosis (due to incomplete/poor quality MRIs or no central review 
of MRIs), or had excess residual tumor (>1.5 cm2) on review, had worse 
outcome. The latter observation might however be dependent on 
medulloblastoma subgroup. A retrospective analysis of 787 medulloblastoma 
patients, with radiographic central review as well as molecular subgrouping, 
concluded that the prognostic benefit of increased extent of resection was 
attenuated after MB subgroup was taken into account (Thompson et al. 
2016). Only in Group 4 tumors a survival benefit from GTR was found, but 
not in WNT, SHH, or Group 3 tumors.  
Impact of relapse site on prognosis 
The majority of relapses reported in Paper I were metastatic within the CNS, 
with or without involvement of the posterior fossa, consistent with several 
previous reports (Bouffet et al. 1998, Pizer et al. 2011, Packer et al. 2012, 
Bode et al. 2014). In the paper from Bowers et al. however, a higher 
proportion of isolated local relapses (51 %) was reported, the remainder 
being metastatic (Bowers et al. 2007).  
Isolated PF relapse (i.e. in the posterior fossa only) was found in 18 % of 
relapses and was associated with longer survival compared to all other 
relapse patterns. We found no difference in survival when comparing all 
isolated relapses (i.e. PF or non-PF) vs combined relapses. In contrast, 
Bouffet et al. found the opposite association, i.e. an isolated relapse was 
associated with better survival compared to a combined relapse, but a local 
PF relapse was not associated with longer survival compared to a distant or 
combined relapse (Bouffet et al. 1998). In line with our finding, Bowers et al. 
reported isolated PF relapse to be associated with longer survival (Bowers et 
al. 2007), and also Bode et al. found longer PFS in patients with localized PF 
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relapse compared to disseminated (Bode et al. 2014). Packer et al. found 
about the same frequency (20.6 %) of isolated PF relapses in the COG A9961 
trial, but the prognostic impact of relapse site was not reported (Packer et al. 
2012). 
No extra-CNS metastases where reported neither in the HIT-SIOP PNET4 
trial nor in the equally large COG-trial A9961 (Packer et al. 2012, Sabel et al. 
2016). Such metastases, usually found in bone (but also in lymph nodes, liver 
and lungs) were reported quite frequently (in up to 18 % of relapses) when 
medulloblastomas were treated with surgery + radiotherapy but without 
chemotherapy (Kleinman et al. 1981). This relapse pattern now seem very 
rare, probably due to the addition of chemotherapy (Tarbell et al. 1991). 
Median time to relapse and late relapses 
We report in Paper I a median time to relapse of 26 months (mean 30 
months). Bouffet et al. reported a shorter median time to relapse, 315 days 
from surgery (Bouffet et al. 1998). Other studies have reported a slightly 
longer median time to relapse, at 2.3-2.5 years (Pizer et al. 2011, Bode et al. 
2014). Bowers et al. reported a mean interval of 1.9 years from primary 
diagnosis to relapse (Bowers et al. 2007).  
Six of 72 (8.3 %) relapses in Paper I were late relapses (>5 years after 
primary diagnosis), which is comparable to previous reports. Others have 
reported 8.7 % and 10.3 % late relapses, defined as >4 or >5 years from 
primary diagnosis respectively (Bouffet et al. 1998, Packer et al. 2012). In the 
latter study a significant proportion of late relapses (57 %), were isolated 
relapses in the posterior fossa (Packer et al. 2012). A similar trend for late 
relapses more commonly being isolated posterior fossa relapses was found in 
the present study (Paper I).  
To summarize, the median time from primary diagnosis to relapse varies 
from 315 days to 2.5 years in different series, albeit in slightly different 
medulloblastoma populations. Late relapses (>4-5 years after primary 
diagnosis) are uncommon, but amount to 8-10 % of recurrences. A recent 
retrospective epidemiological study found the probability of dying from a 
neurological cause was <5 % eight years after medulloblastoma diagnosis, 
and stated that patients alive eight years after diagnosis are likely long-term 
survivors (Weil et al. 2017). 
Survival after relapse 
We report a median survival time after relapse of 1.5 years (mean 1.9 years), 
and a 5-year OS after relapse of 6 % (Paper I). In the study by Bouffet and 
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coworkers, 44/46 patients died, and the median survival after relapse was 
only five months. The shorter survival might be explained by the inclusion of 
patients with high risk (metastatic) disease, and thus potentially more 
aggressive disease, at primary diagnosis (Bouffet et al. 1998). Others have 
reported a median OS of 1.6-1.8 years after relapse and a 5-year OS of 8.2 - 
29.5% (Bowers et al. 2007, Pizer et al. 2011). The relatively high 5-year OS 
of 29.5 % in the study reported by Bowers et al, included only the 41 patients 
who received relapse treatment and excluded five patients that did not receive 
any treatment, and subsequently died shortly thereafter (Bowers et al. 2007). 
Furthermore, a substantial proportion of the patients had not previously 
received radiotherapy, which could explain the higher number of survivors 
(Bowers et al. 2007). Bode et al reported a median OS of 1.75 years (21.0 
months) for the whole cohort (mainly recurrent medulloblastomas, but also 
including 12.5 % stPNET/pineoblastomas) (Bode et al. 2014).  
Relapse prognosis in relation to histology and biology 
The histological subgroup (at primary diagnosis) had no impact on time in 
first remission, relapse pattern, or survival after relapse. Since biopsy of the 
relapsed tumor was not performed in the majority of cases, we could only 
analyze histological and biological factors in the primary tumor. This is a 
limitation, since it has been demonstrated that significant biological changes 
can emerge between primary diagnosis and relapse, e.g. MYC-family gene 
amplifications or TP53 pathway defects (Hill et al. 2015). The biological 
analyses were also limited by lack of remaining tumor material, and e.g. 
retrospective MB subgrouping could not be achieved other than the 
prospectively delineated WNT-MB group. It seems however, that MB 
subgroup remains stable between the tumor at diagnosis and at relapse 
(Ramaswamy et al. 2013, Hill et al. 2015).  
Analysis of β-catenin status, Chr 17(im)/diploid background, and 
MYC/MYCN status did not reveal an impact on time in CCR1, localization 
of the recurrent tumor, or survival after relapse, but there was a limited 
number of cases in some biomarker subgroups. For example, there were only 
eight relapsed cases with β-catenin nuclear positive status (WNT-MB), but 
the prognosis after relapse was equally poor also for these tumors compared 
to non-WNT cases. 
Diagnosis of relapse 
Histological verification of the relapse diagnosis was achieved in a minority 
of cases. In the majority, diagnosis was based on MRI findings, sometimes 
together with CSF cytology. The majority of relapses (69%) were found on 
surveillance MRI in asymptomatic patients, and seemingly these patients had 
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a longer survival after relapse compared to patients diagnosed due to 
symptoms. This confirms findings in previous studies (Torres et al. 1994, 
Bouffet et al. 1998, Minn et al. 2001), but is probably due to the effect of lead 
time and length time bias. Eventually almost all patients died due to 
progressive disease, and there was no difference in OS (from primary 
diagnosis) between the diagnostic groups. 
The role for surveillance MRI has been questioned, and especially so for 
spinal MRIs, since isolated spinal relapse without concurrent findings on 
cranial MRI has been described as rare (or absent) in previous studies 
(Saunders et al. 2003, Bartels et al. 2006, Perreault et al. 2014). It should be 
noted however, in the study by Saunders and coworkers, a spinal MRI was 
included in the surveillance protocol only if the patient had disseminated 
disease at primary diagnosis or when a recurrence was detected by cranial 
MRI, which might explain the absence of isolated spinal relapses (Saunders 
et al. 2003). Perreault and coworkers found 4/27 (14.8 %) isolated spinal 
relapses when reviewing the surveillance MRIs of 89 medulloblastoma 
patients (Perreault et al. 2014). In Paper I, 17 % of relapses were both 
asymptomatic and confined only to the spine. Six more isolated spinal 
relapses were diagnosed due to symptoms. A substantial number (44 %) of 
MRIs diagnosing these isolated spinal relapse were centrally reviewed, 
indicating that this relapse pattern occasionally occurs. The detection rate of 
isolated spinal recurrences is however low, and has been estimated to 7/1000 
MRIs (Perreault et al. 2014). Considering the poor prognosis after 
medulloblastoma relapse, the benefit of early discovery of relapse by 
surveillance MRI remains unclear, but could be justified in the perspective of 
possible inclusion in a relapse study. 
Second malignant neoplasms 
The number of SMNs (n=3) in Paper I is somewhat lower than expected. 
The equally sized COG A9961 study reported fifteen cases, albeit with 
almost two years longer (median) follow up (Packer et al. 2012). More SMNs 
should therefore be expected with time. Given the fairly low frequency of 
tumor biopsies performed at relapse, some SMNs might have been 
misdiagnosed as relapses, something that also might explain the low number 
of SMNs in Paper I. 
Relapse treatment 
All but four patients received some form of treatment for the recurrent tumor, 
most commonly chemotherapy. Since there was no common relapse protocol, 
the treatments used in Paper I varied significantly. This makes it difficult to 
draw any firm conclusions, e.g. regarding the efficacy of specific 
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chemotherapy regimens, and the results should be interpreted with caution. 
No patients received antiangiogenic/metronomic therapy according to the 
currently on-going MEMMAT or COMBAT trials (Sterba et al. 2010, Peyrl 
et al. 2012).  
There was a fairly low usage of intrathecal chemotherapy (17/66, 26 %) 
considering that 82 % of patients had a metastatic relapse. Different 
intrathecal drugs were used, and the role of intrathecal chemotherapy in 
recurrent medulloblastoma was difficult to evaluate. Only 43 % (9/21) of 
patients with positive CSF cytology received intrathecal chemotherapy.  
Both HDSCR and surgery were more likely to be used in isolated PF 
relapses, the relapse pattern associated with the longest OS after relapse. We 
found no benefit of HDSCR however (used in 21 % of all cases), or focal re-
irradiation (22 % of cases), whereas surgery was associated with longer OS 
after relapse. Even though gross total resection was obtained in < 50 % of 
procedures, surgery should be considered in selected cases. This in light of 
the positive impact on prognosis, but also due to the value of obtaining tumor 
tissue for diagnosis and biological studies. 
Strengths and limitations 
One of the strengths with the study is the long-time follow up of a large 
cohort of standard risk medulloblastoma patients, treated according to the 
same protocol in multiple centers across Europe. This reduced bias from 
treatment at single/few (tertiary) centers and also selection bias. The study 
shows the outcome of relapse treatment without the use of a common relapse 
protocol and gives a survival curve based on a variety of treatments to which 
future studies could be compared. 
 
The study has limitations, e.g. the lack of consistent central review of MRIs 
at relapse. Patients were considered to have relapse or secondary tumors 
based on institutional determinations, less than half of MRIs were centrally 
reviewed. The importance of central review has been shown e.g. in the COG 
A9961 study, where central review after the trial found “unequivocal 
evidence of residual or metastatic disease” in 30/409 (7.3 %) of included 
patients; a misclassification that resulted in under-treatment of these high risk 
patients, and subsequently poorer survival (Packer et al. 2006). In Paper I a 
central review of all MRIs at relapse would have been ideal, but this was 
deemed not feasible given the high number of treatment centers and 
difficulties in retrospectively retrieving the MRIs.  
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Another limitation of the study is the low frequency of tumor biopsy at 
relapse, 24 %. This low frequency is perhaps understandable, since MRI 
often is considered sufficient for relapse diagnosis and a biopsy of a CNS 
tumor is no trivial procedure. A biopsy in a patient who is unlikely to be 
cured also raises ethical concerns, since (unnecessary) surgery could 
potentially lead to further morbidity. Furthermore, the result of the 
histopathological/biological analysis is not (at present) used to guide relapse 
treatment. On the other hand, not performing biopsies can lead to 
misdiagnosis of a SMN as a medulloblastoma relapse, something that could 
lead to incorrect therapy. Radiation necrosis, unspecific contrast enhancing 
nodules in the radiation field, and even infections can sometimes mimic 
recurrent tumor on MRI (Muscal et al. 2009, Fisher et al. 2012, Weintraub et 
al. 2014). MRI spectroscopy, MRI perfusion and PET can sometimes be of 
help in the differential diagnosis, but histological confirmation should be 
used more frequently. Furthermore, if targeted therapy is considered for 
treatment of recurrent tumors, it is vital to look for the target in the recurrent 
tumor, not only in the primary tumor, since the target might have disappeared 
during clonal evolution (Morrissy et al. 2016). 
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4 PAPER II AND III (ACTIVE VIDEO 
GAMING STUDY) 
4.1 Specific aims for Paper II and III  
To evaluate if regular, home-based active video gaming (AVG) (with online 
coaching), could be used to achieve regular, enjoyable, physical exercise in 
children treated for brain tumors and to: 
1) Explore the effect of the intervention on physical activity 
levels, during gaming sessions, and overall (Paper II).  
 
2) Evaluate compliance to the intervention over time, as well as 
the general feasibility of the method (Paper II).  
 
3) Explore the effect on cognitive function (Paper III). 
 
4) Investigate the effect on motor function (Paper II). 
 
5) Investigate the effect on the performance of activities of 
daily living (ADL) (Paper III). 
4.2 Material and methods (Paper II and III) 
Inclusion and exclusion criteria 
Children, 7-17 years old, who had completed treatment for a brain tumor 
between one and five years earlier, were eligible for inclusion. Previous 
treatment with cranial radiotherapy was mandatory, but treatment 
combinations including surgery and/or chemotherapy were allowed. The cut-
off of one year was chosen to reduce the risk of tumor relapse occurring 
during the study period, and the five year cut-off was arbitrarily chosen. 
Patients were excluded if not in clinical remission, if they were in a medically 
unstable situation (e.g. tumor progression), or if they had another medical or 
behavioral condition making them unable to understand or complete the 
intervention or assessment measures, e.g. severe motor/sensory deficits. 
Patients with conditions that could be worsened by the intervention, such as 
photosensitive epilepsy, were also not allowed to participate. Participants had 
to speak Swedish. The study was approved by the Regional Ethical Review 
Board in Gothenburg. 
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Figure 6. Study design. (SWA: SenseWearPro2 Armband measurements for one week)  
 
Study design 
Participants were randomized to either start with the intervention period 
(intervention group) or a waiting list period (control group) (Figure 6). The 
intervention consisted of AVG for 10 weeks, aiming for a minimum of 30 
minutes of AVG per day at least five days a week, and weekly coaching 
sessions. An extension of the period from 10 up to 12 weeks was allowed, to 
compensate for weeks being away or ill. During the waiting list period the 
participants were asked to refrain from AVG but otherwise live their life as 
normal. Other possible treatments, e.g. physiotherapy or occupational 
therapy, could continue as before during both the intervention period and the 
waiting list period, although this was not registered. At half-time the groups 
crossed over. All participants were tested at three time points, before and 
after each period (Figure 6). All testers were blinded to the allocated 
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randomization group. Tests included cognitive tests, assessments of motor 
function and execution of ADL. Physical activity levels were recorded 
continuously for one week at baseline, and every second week during the 
AVG period (see below).  
Randomization by minimization 
The minimization method was used to randomize between treatment groups 
(Altman and Bland 2005). With the minimization method, the randomization 
group allocated to the next study participant depends partly on the 
characteristics of those participants already enrolled, thus minimizing the 
imbalance between the groups across multiple factors. The groups were 
balanced for the following variables: sex, age at randomization, age at 
radiotherapy, age group (7-13 years or >13 years), and type of radiotherapy 
(focal vs craniospinal). 
Gaming equipment and games 
An off-the-shelf motion-controlled video console, the Nintendo Wii 
(Nintendo Co. Ltd., Kyoto, Japan), was used for active video gaming. The 
Wii is controlled by one or two hand-held remote controls, and requires 
movement to play the games. Each child received two pairs of controls, 
which enabled them to play with friends, and a balance board, the Wii Fit. 
The balance board was used for balance games, as well as some aerobic type 
games. The games were pre-tested by the investigators and chosen mainly to 
stimulate physical activity and gross body movements, but also included less 
physically demanding games such as balance games. Since the intensity of 
the games varied, participants were instructed to start every session with a 
physically more demanding game for at least 10 minutes, before considering 
switching to a slower paced game. The participant did not get access to all 
games from the start. Instead new games were introduced throughout the 
intervention period. This was done by the coach, in dialogue with the 
participant, to increase motivation and reduce attrition. The following games 
were used: Wii Sports (13/13 participants), Wii Sports Resort (13/13), Wii 
Fit (13/13) and Wii Fit plus (11/13). Several dance games were also used: 
Just Dance 1–3 (12/13) and Michael Jackson – the Experience (5/13).  
Home visits were done at the start and end of the intervention period. During 
the first home visit, the study coach and a technician installed and tried out 
the equipment together with the family, and the participant performed a 
familiarization gaming session. The participants also created their own 
unique Wii avatar and were instructed not to let anyone else use it. At the end 
of the intervention period all equipment was collected. 
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Monitoring of energy expenditure and gaming time 
To register energy expenditure (EE) levels, participants wore a multisensory 
activity monitor, the SenseWearPro2 Armband (SWA) (BodyMedia Inc., 
Pittsburgh, PA, USA), continuously (daytime) for one week at baseline, and 
every second week during the intervention period (Figure 6). The SWA is 
attached as an armband, with the sensor touching the skin on the backside of 
the upper right arm. It registers input from multiple physiological sensors 
(skin temperature, near-body temperature, heat flux, galvanic skin response 
and a biaxial accelerometer). It is powered by one AAA battery for up to 14 
days and has a data storage capacity of 10 days. Since it is not water proof it 
cannot be worn during water-based activities.  
With the assistance of the parents, registered SWA data were uploaded to a 
secure server at the end of each recording week. Data from these recordings, 
together with information on the participant´s age, sex, weight and height, 
were used to estimate EE levels, using the SenseWear Professional Software 
(version 6.1 with algorithms 2.2). The EE levels were presented as Metabolic 
Equivalent of Task (MET). The MET, or just metabolic equivalent, is a 
physiological measure of the energy cost of physical activity. It is defined as 
the ratio of the metabolic rate during a specific activity to the resting 
metabolic rate (Ridley and Olds 2008, Ainsworth et al. 2011). The metabolic 
rate during rest is assigned MET=1 and, e.g. an activity with the MET-value 
3, would require three times the energy consumption compared to rest. To 
assess time spent at different EE levels, the following cut-off points were 
used:  
 Sedentary = MET < 1.5  
 Light physical activity = MET 1.5–2.9  
 Moderate physical activity = MET 3.0–5.9  
 Vigorous physical activity = MET > 6.0 
These are cut-off points previously defined for adults, but found to be similar 
for physical activities in children (Ridley and Olds 2008). The amount of 
moderate physical activity is often combined with vigorous physical activity, 
and presented as MVPA (moderate and vigorous physical activity). The 
SWA and software have been validated for total EE in children, both for 
activities under controlled laboratory conditions (Arvidsson et al. 2007, 
Arvidsson et al. 2009b, Lee et al. 2014), and under everyday living 
conditions (Arvidsson et al. 2009a, Calabró et al. 2013). 
The participants registered the date, start- and stop times of each gaming 
session in a gaming diary. In addition, the Wii console recorded how much 
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time was spent playing each game on any given day, and by which avatar 
(player). We expected that this information could replace a detailed gaming 
diary and used these data to compare the playing time noted by the 
participants in the gaming diary, to the gaming time recorded in the console. 
Before and after the intervention period, parents and children were 
interviewed about the children’s leisure time activities, especially the amount 
of regular physical exercise. 
Comment: The SWA has a “time stamp” button which we initially thought 
could be used to mark the start- and stop times of gaming sessions. However, 
there is no indication on the armband itself showing if the button has been 
pressed or not, which turned out to be a problem. The participant often forgot 
to press it, or forgot he/she had already pressed it and thus pressed it again, 
inadvertently indicating a session stop. Fortunately, this was quickly 
discovered and the “time stamp” was replaced with the gaming diary. A more 
detailed gaming diary, (e.g. including specific games played), would have 
been ideal but also more cumbersome for the participants, and we therefore 
settled for just start and stop times. As described above, the Wii console 
automatically records gaming time and games used, but this registration has 
several limitations. Most Wii games consist of several sub-games. These 
different games require varying levels of physical activity to be played. The 
console only records the main game inserted into the console, and gives no 
information on the different sub-games used. Furthermore, it records the time 
a specific avatar (gamer) is logged in, but if you forget to log off at the end of 
the session (and leave the console on), the registration continues, and logs a 
falsely long gaming time. To associate MET levels to specific sub-games, or 
extracting the active gaming time solely from console data, was therefore not 
possible. It could however be used to confirm that entries in the gaming diary 
were correct. 
Coaching during the intervention period 
Coaching was used during the intervention period to encourage participants, 
and maintain compliance, and to check that study instructions were being 
followed (Hayes and Kalmakis 2007). To provide some background 
information, participants completed two surveys before the first coaching 
session: one about school, friends and interests and one about how they 
usually spend their leisure time. Coaching was performed mainly by the same 
research nurse, over the Internet, using laptops with communications 
software (Adobe Connect Pro, Adobe Systems Inc., San Jose, CA), webcams, 
and headsets. During the weekly coaching sessions, the coach performed 
semi-structured interviews with the child regarding the past week’s AVG 
sessions. The coach encouraged the participants to perform the AVG, 
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maintaining an optimistic attitude, and also challenged the child to try new 
games and/or to compete. No coaching was performed during the waiting list 
period. 
Cognitive assessment 
The cognitive tests were selected in close collaboration with a psychologist 
experienced in evaluating children with cognitive difficulties after brain 
tumor treatment. Tests were chosen to cover the areas most commonly 
affected, including IQ, attention (selective, sustained and visual), working 
memory (verbal and visual-spatial), memory, verbal learning, executive 
function, processing speed, and social ability. For a full description of tests 
used, including references, see Supplement table I in Paper III. In short, the 
tests were:  
 Wechsler Intelligence Scale for Children (WISC-IV). A 
measure of IQ was computed from an abbreviated version of 
WISC-IV, using four subtests: digit span, similarities, block 
design, and coding B.  
 Conners’ Continuous Performance Test II (CPT II) 
(Sustained Attention). 
 Map Mission, a subtest from the Test of Everyday Attention 
for children (Selective attention). 
 Visual Scanning, a subtest in the Trail Making Test version 
of the Delis-Kaplan Executive Function System (D-KEFS) 
test battery of executive functions (Visual attention). 
 The Digit Span subtest of the Wechsler Intelligence Scale 
for Children-version IV (WISC–IV) (Verbal short-term/ 
working memory/general working memory). 
 Auditory Consonant Trigrams (ACT) (Verbal working 
memory). 
 Spatial Span, a subtest from the Wechsler Nonverbal Scale 
of Abilities (Spatial working memory). 
 Rey Auditory Verbal Learning Test (RAVLT) 
(Immediate memory, verbal long-term memory and 
learning). 
 The subtest Information from WISC-IV (General 
knowledge). 
 Rey Complex Figure Test (Visual-spatial memory). 
 Coding, a subtest from the WISC-IV (Processing speed and 
implicit learning). 
 The Controlled Oral Word Association Test (COWAT) 
(Executive function  Verbal fluency). 
Magnus Sabel 
57 
 Stroop Test, Victoria version (Executive function). 
 The Trail Making Test from D-KEFS (Executive function). 
 Picture Arrangement, a subtest from the Wechsler 
Nonverbal Scale of Abilities (Social ability). 
The cognitive tests were administrated in a quiet room, usually at the 
hospital, by a trained psychologist. Their order of presentation was designed 
to facilitate the child’s engagement, (with easy tests at the beginning), and to 
avoid the risk of interference in the period between immediate and delayed 
recall of Rey Auditory Verbal Learning Test and Rey Complex Figure Test. 
The test battery was delivered in five sets, with four small pauses, to allow 
the child to recover. Three tests had alternative forms available: Map 
Mission, Rey Auditory Verbal Learning Test and Rey Complex Figure Test. 
For these tests, the original form was presented at the first and third 
assessments whereas the alternative form was presented at the second 
assessment session.  
Assessment of motor performance  
Assessments of physical functioning were done at the hospital’s 
physiotherapy department by an experienced physiotherapist, using the 
complete form of the Bruininks–Osteretsky Test of Motor Performance, 
Second Edition (BOT-2) (Bruininks and Bruininks 2005). BOT-2 is designed 
to characterize motor performance and measures fine and gross motor skills 
in patients, 4–21 years of age. The BOT-2 has moderate to high inter-rater 
and test–retest reliabilities in children (Bruininks and Bruininks 2005, Wuang 
and Su 2009). It has been used in studies in pediatric neurological 
populations as well as pediatric oncological conditions, including brain 
tumors (Johnson et al. 2010, Dahl and Emanuelson 2013, De Luca et al. 
2013, Piscione et al. 2014).  
BOT-2 has 58 items with eight subscales, which are combined into four 
motor area composite scores:  
 Fine Manual Control (includes the subscales Fine Motor 
Precision and Fine Motor Integration),  
 Manual Coordination (includes Manual Dexterity and 
Upper-Limb Coordination),  
 Body Coordination (includes Bilateral Coordination and 
Balance), and  
 Strength and Agility (includes Running Speed and Agility 
and Strength) 
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Assessment of the execution of ADL 
To evaluate the ability to perform both personal and instrumental ADL we 
used the Assessment of Motor and Process Skills (AMPS) (Fisher and Jones 
2012). The evaluations took place in each participant’s home. AMPS 
measures the quality of a person’s performance during ADL tasks. An 
AMPS-trained and calibrated rater (calibrated to compensate for harshness or 
softness in the judgment of performance) scores performance in two tasks 
according to explicit, specific criteria, using a 4-point ordinal scale; 
(1=unacceptable performance, 2=ineffective, 3=questionable, 4=competent). 
Tasks are selected from the AMPS collection of analyzed tasks (e.g. setting 
the dinner table for four, or making a fruit salad), and should be familiar to 
the person tested and identified by him or her as presenting problems in 
everyday life.  
During the execution of the tasks, the rater evaluates and scores 16 motor 
skills and 20 process skills. Motor skills are observable actions used to move 
oneself and objects within a task environment, and process skills refer to the 
observable actions of a person to organize and adapt task actions to prevent 
or overcome problems while performing a functional task (e.g. searching, 
locating, and gathering needed objects; initiating, sequencing, and 
terminating actions appropriately). Raw scores are adjusted for the difficulty 
of the performed task and the severity of the examiner, and converted to a 
linear measure of motor and process skills using many-facet Rasch analysis, 
and are expressed as interval-scaled log-odds probability units (logits) (Fisher 
1993, Linacre 1994). This was done using the AMPS software, version 2005. 
A higher ADL motor or ADL process ability measure indicates that the 
individual is more able.  
AMPS has been validated for use in Sweden (Bernspång and Fisher 1995). 
Several studies of the psychometric properties of AMPS, in different 
populations, age groups and settings, suggest that it is well suited to both 
clinical and research applications (Fisher et al. 1992, Dickerson and Fisher 
1993, Gantschnig et al. 2013). 
4.2.1 Statistical methods 
To detect a mean difference of 1 SD between the two randomized groups, 
with a power of 80 % and an alpha of 0.05, a sample size of 34 was 
estimated. We expected this number to be difficult to achieve, given the 
population base and the rarity of the underlying condition, and therefore 
designed an exploratory study with a pseudo crossover design. This design 
allowed us to evaluate all children´s performance before and after the 
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intervention period (within-subjects design), as well as to compare the 
randomized groups after the first period (parallel group analysis). Since a 
carry-over effect from the intervention period could not be excluded, we 
choose not to do a conventional crossover analysis.  
As a primary analysis we performed Fisher’s paired non-parametric 
permutation test of the change in outcome variables during the intervention 
period, for all individuals (Good 2000). A parallel group analysis was done as 
a sensitivity analysis, comparing the change in outcome variables during the 
first period, between the randomized groups. We used analysis of covariance 
(ANCOVA) to adjust for the baseline values, with randomization group and 
baseline scores as independent variables.  
A secondary analysis, measuring the correlation between activity levels and 
gaming time and the change in outcome variables, was performed using 
Pitman´s non-parametric permutation test (Good 2000), and described with 
Pearson correlation coefficient. To calculate the effect sizes (in Paper III) 
we used the Standardized Response Mean (SRM), i.e. the ratio between the 
mean change score and the standard deviation of that change score within the 
same group. 
To compare the distribution between the randomization groups we used 
unpaired t-test for continuous variables and Fisher´s exact test for categorical. 
Wilcoxon signed ranks test was performed to compare EE levels (METs) at 
baseline with measurements from the intervention period. To allow 
comparison of activity levels regardless of SWA wearing time, the daily 
duration of different activity levels were first normalized to 14 hours of 
SWA-wearing. This procedure was also used for comparing active video 
gaming time between different time periods of the intervention.  
To further describe the patient group and allow comparison of BOT-2 and 
AMPS results to previous publications and normative data we also, post-hoc, 
calculated the Z scores for theses variables. For comparison with normative 
data we used one-sample t-test. Post-hoc analyses were done using SPSS 
statistics for Windows (version 20, IBM Corp., Armonk, NY, USA). All 
other analyses were done using SAS Software (version 9.3, SAS Institute, 
Cary, NC, USA). All test were two-sided, and were based on the intention to 
treat (ITT) population. For between-group analyses, the significance level 
was set to p=0.05, but for comparisons to normative data, the significance 
level was reduced to p=0.01 due to multiple comparisons. 
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4.3 Results (Paper II and III) 
All patients in Western Sweden diagnosed with a brain tumor after 2003, 
who had received radiotherapy and were < 17 years at the start of the study 
(n=33), were identified through the Swedish Childhood Cancer Registry and 
hospital records. Six had been off treatment for more than five years, four 
were too young (< 7 years), four were receiving treatment for a recurrence, 
two could not speak Swedish and one was excluded because of autism. 
Sixteen patients, fulfilling all criteria, were identified. Three declined to 
participate.  
The demographics and randomization results are presented in Table 3. Ten of 
13 had been treated for high grade (malignant) tumors. The remaining three 
had midline supratentorial low grade astrocytomas, not amenable for surgical 
removal. The mean time from radiotherapy to randomization was 4.4 years 
(median 4.2, range 1-12.3 years), and did not differ between the groups 
(p=0.76). The mean IQ score was > 1 SD below the population mean, at 76.8 
(median 77, range 63-90). There was no difference between groups regarding 
age, sex, tumor location, treatment, and baseline IQ score, or previous Wii 
experience (Table 3).  
4.3.1 Compliance and gaming time 
All included children (n=13) completed the trial. The mean gaming session 
lasted 47 minutes (median 38 min). The intervention period (10-12 weeks) 
lasted for mean 71 days (median 70 days, range 60-82), and the participants 
performed active video gaming on mean (=median) 51 days (72 % of 
available days). The preset target of active video gaming on at least five out 
of seven days per week was reached (or surpassed) by ten children, who were 
within 95 % of the target frequency (or above). Three children reached 
between 75-89 % of the target frequency. Compliance was generally good. 
The main reasons for non-compliance were illness or travel.  
When splitting the intervention period in five equal parts (P1-P5) and 
comparing the AVG frequency, the most frequent active video gaming was 
seen in the first fifth of the intervention period, with AVG performed on 
mean 5.8 days per week. After this intense start the AVG frequency dropped 
significantly, to mean 4.7 days/week (p=0.01, Wilcoxon signed ranks test), 
but recovered during the following weeks to 5.2 days/week and remained 
stable for the remainder of the intervention period. 
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Table 3. Demographics and randomization results. (Adapted from Paper 
II and Paper III) 
  Randomization group  
Characteristic 
All 
(n=13) 
Intervention first 
(n=7) 
Waiting list first 
(n=6) 
p-value 
     
Age at 
randomization, y 
12.5 (2.9) 11.9 (3.6) 13.2 (1.9) 0.43 
Sex     
 M/F 6/7 (46/54 %) 3/4 (43/57 %) 3/3 (50/50 %) 1.0 
Tumor type  Anaplastic 
astrocytoma 
Germinoma (x2) 
Medulloblastoma 
Central Pilocytic 
astrocytoma (x2) 
ST-PNET 
Choroid plexus 
carcinoma 
Germinoma 
Medulloblastoma (x2) 
Central Pilocytic 
astrocytoma 
ST-PNET 
 
Tumor location     
 PF/ST 3/10 (23/77 %) 1/6 (14/86 %) 2/4 (33/67 %) 0.56 
Type of RT     
 Focal/CSI 3/10 (23/77 %) 2/5 (29/71 %) 1/5 (17/83 %) 1.0 
Age at RT 8.4 (2.6) 8.0 (3.4) 8.9 (1.6) 0.53 
Neurosurgery 9 (69 %) 4 (57 %) 5 (83 %) 0.56 
Chemotherapy 12 (92 %) 6 (85 %) 6 (100 %) 1.0 
VP shunt 4 (31 %) 2 (29 %) 2(33 %) 1.0 
Baseline IQ 76.8 (8.0) 77.3 (10.2) 76.2 (5.4) 0.81 
Previous Wii 
experience 
7 (54 %) 4 (57 %) 3 (50 %) 1.0 
Regular weekly 
physical activity 
 
5 (38 %) 2 (29 %) 3 (50 %) 0.59 
 
For categorical variables n (%) is presented. For continuous variables Mean (SD) is 
presented. CSI craniospinal irradiation, PF Posterior fossa, PNET Primitive 
neuroectodermal tumor, RT radiotherapy, ST Supratentorial. Continuous variables 
analyzed with unpaired t-test, categorical with Fisher´s exact test, both two-sided, 
comparing randomization groups. 
4.3.2 Energy expenditure levels 
The AVG frequency pattern described above (in section 4.3.1), with the most 
intensive active video gaming in the first fifth of the intervention, was also 
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evident when analyzing SWA measurements. During the initial weeks (P1), 
the sedentary time (MET < 1.5) decreased by 14 % compared to baseline 
(p=0.004 Wilcoxon signed ranks test), but slowly rose to baseline levels 
thereafter. There was a trend for an increase in MVPA from mean (median) 
115 (110) min/day to 139 (116) min/day (p=0.099 Wilcoxon signed ranks 
test) during P1, but for the remainder of the intervention there was no change 
compared to baseline.  
The overall mean daily EE level was not affected by the intervention (1.9 
MET at baseline and 2.0 during AVG weeks, n.s.). The mean daily MET 
value increased during the intervention period (compared to baseline) in six 
children, was unchanged in five and decreased in two, although these changes 
were not statistically significant. Five children performed other types of 
regular physical exercise, and only one in this group increased the daily mean 
MET value (one decreased and three remained at the same level). In the 
remaining eight children, without other regular physical exercise, five 
increased their daily MET value, in one case it decreased and for the 
remaining two it did not change. The mean physical activity level during 
AVG sessions was of moderate intensity, at mean 3.0 MET (median 3.0, 
range 1.2-5.7).  
4.3.3 Internet coaching and technical issues 
The mean (and median) number of coaching sessions during the intervention 
period was 10 (range 8–11), usually once a week, with a mean duration of 18 
minutes. It is our impression that weekly coaching sessions helped the 
participants to continue with the study, and it enabled the coach to respond 
quickly to signs of attrition, by e.g. introducing a new game, or to help with 
technical problems. The participants rated 36 % of the gaming weeks as 
‘‘fun’’, 52 % as ‘‘OK’’, and 2 % as ‘‘boring’’. No enjoyment data were 
registered in 10 % of the gaming weeks. 
The AVG equipment itself did not cause any substantial technical problems. 
The children managed to both play and connect to the Internet with little or 
no help from their parents. Most technical difficulties were related to the on-
line coaching sessions but the great majority of coaching sessions (89 %) 
were performed as planned; however, 11 % had major technical problems. In 
these cases coaching was done over the telephone. When functioning as 
intended, coaching through video conferencing rather than over the telephone 
had several advantages, such as mutual facial contact and making it possible 
to instruct also with gestures. If the coaching would have taken place at the 
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participant´s home (or at the hospital), a weekly return trip to each participant 
would have amounted to over 1900 km of travelling per week. 
4.3.4 Effects on cognitive test results 
There was no significant change in cognitive test results between tests before 
and after the intervention period (see Paper III for details). There were 
trends for improvement in sustained attention (CPT-II omission, T-score) by 
mean -8.9 (lower score=better; p=0.090; 95 % CI -21.8 to 4.1) and selective 
attention (Map-mission) by mean 0.9 standard points, (p=0.078; 95% CI        
-0.02 to 1.9). The improvement in sustained attention was positively 
correlated to the total active video gaming time (r=0.61, p=0.047) but showed 
no correlation to energy expenditure (MET) parameters. No correlation was 
found between selective attention and active video gaming time or MET-
levels. 
4.3.5 Effects on physical functioning 
At baseline, the participating children had significantly decreased 
performance (Z scores) compared to norms in the following BOT-2 
composite scores:  
Manual Coordination  (mean Z score -1.0, 95 % CI -1.6 to -0.4, p=0.0042)  
Body Coordination  (mean Z score -0.9, 95 % CI -1.4 to -0.4, p=0.0006)   
Strength and Agility  (mean Z score -0.9, 95 % CI -1.6 to -0.3, p=0.0062)  
Performance in Fine Manual Control (and the corresponding sub-tests) was 
normal. The reduced performance in Manual Coordination corresponded to a 
reduced performance in the sub-test Manual Dexterity (mean Z score -1.0, 95 
% CI -1.5 to -0.6, p=0.0007), but not Upper-limb Coordination. The 
decreased performance in Body Coordination corresponded to a reduced 
Balance score (mean Z score -1.2, 95 % CI -1.9 to -0.6, p=0.002) whereas the 
Bilateral Coordination score was within norms (mean Z score -0.4, 95 % CI   
-0.8 to 0.10, p=0.11). Finally, the sub-tests making up the composite score 
Strength and Agility were both sub-normal, i.e. Running Speed and Agility 
(mean Z score -1.0, 95 % CI -1.7 to -0.3, p=0.007) and Strength (mean Z 
score -0.9, 95 % CI -1.4 to -0.4, p=0.003). Over the intervention period 
(within-subjects analysis), the Body Coordination score improved by 15 %, 
(mean improvement 4.55 scale score points, 95 % CI 0.45 to 8.64, p=0.021). 
An analysis of the sub-scores forming the Body Coordination score, revealed 
a statistically significant 17% improvement in the Bilateral Coordination 
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score over the intervention period, (mean improvement 2.18, 95 % CI 0.31 to 
4.05, p=0.047), but no change in Balance score. Regarding Body 
Coordination, the statistical significance was lost in the parallel group 
analysis (mean improvement 4.13 scale score points, 95 % CI -4.06 to 12.33, 
p=0.28).  
4.3.6 Effects on ADL performance 
At baseline, the participating children had significantly reduced Z scores 
compared to norms in both AMPS motor score (mean Z score -1.7; 95 % CI  
-2.5 to -0.93, P=0.001), and AMPS process score (mean Z score -1.1; 95 % 
CI -1.8 to -0.45, p=0.003).  
ADL motor performance 
The mean motor skills score improved significantly over the intervention 
period (within-subjects analysis), by mean 0.51 logits (95 % CI 0.16 to 0.85, 
p=0.012). The motor skill Z score also improved after the intervention, but 
was still below the norm (mean Z score -1.1, 95 % CI -1.7 to -0.46, p=0.003). 
In the parallel group analysis the intervention group improved more than the 
control group in motor skills score, but this was not statistically significant 
(mean difference 0.47 logits, 95 % CI -0.02 to 0.96, p=0.059). 
ADL process performance 
The mean process skills score also improved over the intervention period 
(within-subjects analysis), by mean 0.50 logits (95 % CI 0.27 to 0.74, 
p=0.0020). Translated into Z score, the post-intervention process score 
reached the age-expected norm (mean Z score 0.20, 95 % CI -0.24 to 0.64, 
p=0.34). In the parallel group analysis, the intervention group improved by 
mean 0.47 logits compared to the control group (95 % CI 0.059 to 0.89), an 
improvement that was statistically significant (p=0.0296). No correlation was 
found between improvement in AMPS motor/process scores and active video 
gaming time or MET-levels.  
When looking at the AMPS motor and process scores over time, an 
improvement was seen after the intervention period but not after the control 
period, contradicting a practice effect from multiple testing (Figure 7). 
Furthermore, looking at the intervention-first group, the positive effect on 
ADL was preserved at the follow up test, 10-12 weeks after the intervention 
period, indicating a sustained effect over time. 
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Figure 7. AMPS scores (logits) over time in the two groups. AMPS motor scores in the upper 
panel and process scores in the lower. 
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4.4 Discussion (Paper II and III) 
This study was, to our knowledge, the first to report on the use of active 
video gaming to mitigate late side effects in childhood brain tumor survivors. 
AVG, stimulated by weekly online coaching was used to encourage near-
daily, moderately intense, physical activity over a period of three months. 
The activity was perceived as fun or OK, and all enrolled participants 
completed the study. Coaching was probably an important factor for 
compliance. In the absence of a non-coached AVG group we cannot 
substantiate this feeling, but it is supported by the results of a randomized 
study that compared AVG with or without weekly coaching, and found a 
higher gaming participation in the coached group (Errickson et al. 2012). 
There were two main reasons for using a crossover design even though a 
conventional crossover analysis was not performed:  
1) It permitted a within-subjects analysis of the effects of the 
intervention, together with a parallel group comparison after 
the first period. A pure within-subjects trial would lose the 
randomization group comparison, and a pure randomization 
study would more likely be underpowered. 
2) All children were allowed to play video games at some 
point; a motivational factor for participating in the trial.  
Active video gaming improved body coordination and ADL performance. It 
is likely that the improvement in ADL was due to both motor improvement 
and a cognitive effect, although the specific cognitive tests failed to find any 
significant improvement. It has been suggested that exercise enhances the 
capacity to use previously encoded memories, i.e. you remember effective 
task strategies (Hill et al. 2011), something that might explain the positive 
impact of exercise on ADL performance. Since no significant changes in 
cognitive tests were found, the question if AVG can improve cognition 
remains unanswered. A full-sized randomized controlled trial should be done 
to answer this question. Building on the findings from this trial, as well as 
other exercise trials aiming to improve cognition, the cognitive assessment 
battery could be narrower in future trials, and focus on executive function, 
working memory, and attention. Tests of academic achievement have in some 
studies been more sensitive than cognitive (IQ) tests (Fouladi et al. 2004, 
Merchant et al. 2014), and could also be considered. We found statistically 
significant improvements in Body Coordination and Bilateral Coordination 
after AVG. One way of assessing if these improvements are clinically 
significant is by estimating the minimal important difference (MID). MID 
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can be defined as the smallest change in the measurement score considered to 
be important by using another anchor score (de Vet et al. 2006). A change 
greater than the MID is by definition clinically important. A study of children 
with intellectual disabilities explored different aspects of the BOT-2 
instrument, and used the physical tasks performance scale as an anchor score 
(Wuang and Su 2009). They found the MID for Body coordination to be 
1.65, and for Bilateral Coordination 1.11. The mean changes presented in 
Paper II were 4.55 and 2.18 respectively, which implies clinically significant 
improvements. Regarding ADL, the mean improvement in AMPS score after 
the intervention was 0.51 logits in motor score and 0.50 logits in process 
score. A change of 0.3 logits is considered clinically relevant (Fisher and 
Merritt 2012). The improvement in AMPS score can therefore be transferred 
to functional gains that can have an influence on the patients´ daily life. 
However, although the effects on ADL performance seem strong and the 
results are encouraging, due to the small sample size they must be interpreted 
with some caution. 
The major limitation of the study is the small sample size, which could lead 
to a type II error (i.e. incorrectly retaining a false null hypothesis). There 
could also be other potential explanations for the lack of cognitive effects 
from the intervention: 
1. Physical activity levels were not increased enough. The mean EE 
levels during AVG sessions reached moderate levels, which is in 
accordance with previous AVG studies (Howcroft et al. 2012, 
O'Donovan et al. 2013). Reaching higher EE levels during AVG is 
possible, but probably harder to achieve in a home setting compared 
to a laboratory setting. The intensity of AVG is more intermittent, 
and EE is less uniform across the gaming session in a home setting, 
probably contributing to lower mean intensity levels (Biddiss and 
Irwin 2010). Regarding the measurement of EE levels with the 
SenseWear Armband, there is a possibility of underestimation of the 
EE level during some high intensity activities. The signal from an 
accelerometer is integrated over a given time interval (epoch), then 
summed and stored. The SWA is restricted to a 1-minute epoch due 
to storage capacity limitations. This sampling rate may not fully 
capture the variability pattern of children, characterized by short, 
intermittent bursts of activity, and the SWA (as other activity 
monitors), has a tendency of underestimating EE at higher intensities 
(Nilsson et al. 2002, Arvidsson et al. 2007). Also, it is possible that 
SWA overestimates activities involving primarily upper body 
movements, and underestimates activities using lower body 
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movements. A validation study for Wii gaming using SWA would be 
desirable. 
2. The intervention period was too short. Exercise intervention studies 
in older adults have resulted in conflicting results and it has been 
proposed that longer intervention periods (≥ 1 year) are necessary to 
get cognitive health benefits (Snowden et al. 2011). However, 
cognitive benefits from exercise has been found in children after 
interventions of similar length as our trial (Davis et al. 2011, de 
Kloet et al. 2012, Riggs et al. 2016). 
3. Interference from non-active video gaming during the waiting list 
period. Non-active video gaming was not restricted and this could 
have interfered with the results. We have no way of controlling for 
this, as it was not measured. Furthermore, we do not know if some 
participants performed active video gaming also during the control 
period. The gaming console was retrieved and not available during 
the waiting list period for the majority of participants, but some 
children had a console of their own. Although we asked the parents 
to refrain the children from using it during the control period, 
compliance to this was not measured.  
4. Interference from other physical exercise or previous AVG 
experience. Some participants (5/13, two in the intervention first 
group, three in the waiting list group) performed regular physical 
exercise (1-3 times/week) along with the trial, which potentially 
could have reduced the effect of the intervention. Regarding previous 
AVG experience, 7/13 had previous Wii experience (4 in the AVG 
group, 3 in the waiting list group). It is possible that higher fit 
children or AVG-experienced children had reduced benefit from 
AVG interventions, due to a ceiling effect. Unfortunately, the small 
trial size prevented reliable sub-analyses regarding this effect. 
5. Lastly, it is possible the intervention had no effect on cognition. To 
clarify this, a larger trial is needed. A study using Nintendo Wii in a 
similar patient population (with acquired brain injury) found 
improvements in cognitive parameters after AVG, indicating a 
cognitive effect, although the study did not include a control group 
(de Kloet et al. 2012).  
In conclusion, the children in the study, previously treated for brain tumors 
with multimodal therapy (including radiotherapy to the brain), had poor 
performance in several functional areas, e.g. motor functions, cognitive 
performance and execution of ADL. Their performance was, in some aspects, 
improved by the intervention, hopefully helping them to manage their 
everyday life better. 
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5 PAPER IV (HYPOTHERMIA STUDY) 
5.1 Specific aim for Paper IV  
The aim for Paper IV was to study, in a rodent model, if the radiation-
induced damage to the neurogenic regions of the brain could be lessened by 
inducing hypothermia directly after brain irradiation. 
5.2 Material and methods (Paper IV) 
Postnatal day 9 (P9) Wistar rats of either sex were randomized to either a 
normothermia group, a hypothermia group or a control group. All subjects 
were anesthetized with an intraperitoneal injection of tribromoethanol, and 
the control animals were then returned to the dam. The two other groups 
received irradiation (8 Gy, single fraction) to the left brain hemisphere using 
a linear accelerator. After irradiation, the animals were placed in containers 
submerged in temperature-controlled water baths (36˚C and 30˚C 
respectively) for eight hours. They were then returned to the dam. Animals 
were kept in a 12-h light/dark schedule (lights on at 07:00 h) with food and 
water available ad libitum. All animal experimental procedures were 
performed in accordance with the European and Swedish animal welfare 
regulations and approved by the Regional Ethical Review Board of 
Gothenburg. 
Tissue preparation and staining 
Seven days after irradiation the animals were deeply anaesthetised with 
sodium pentothal, and transcardially perfusion-fixed with 4% 
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). The brains were 
removed and fixed in formaldehyde for 24 hours. After dehydrating the 
brains with a graded series of ethanol and xylene, they were then embedded 
in paraffin. By this process, the water in the tissue was replaced by paraffin. 
Coronal sections (5 μm thick) were mounted on glass slides and stained with 
thionin/acid fuchsin for morphological analysis. Adjacent sections were used 
for immunostaining. When using paraffin-embedded sections it is beneficial 
to perform antigen retrieval before adding the antibody. This was done by 
boiling the sections in 10 mM citrate buffer (pH 6.0) for 10 min. Nonspecific 
binding was blocked with 4% goat serum in PBS. After blocking, sections 
were incubated with primary antibodies (see below) for 24 hours. The 
following day all unbound antibody was washed off and the biotinylated 
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secondary antibody was added for one hour at room temperature (goat anti-
rabbit biotinylated secondary antibodies). Endogenous peroxidase activity 
was blocked, and visualization was performed using an avidin–biotin–
peroxidase solution. 
Figure 8. Illustration of the rat brain (coronal section) at the level of the dentate gyrus (DG) 
of the hippocampus (upper panel), and the lateral ventricles (lower panel). The magnification 
window in the upper panel shows the different areas of the DG, the granule cell layer (GCL, 
in grey) and the subgranular zone (SGZ, in red). The hilus is defined as the area enclosed by 
the GCL and the imaginary straight (dotted) line joining the tips of the two GCL blades, not 
including the SGZ. The lateral ventricles are seen in the lower panel and the magnification 
illustrates the subventricular zone (SVZ, red line) along the lateral wall of the ventricles, and 
the rostral migratory stream (red dots). 
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Immunohistochemistry 
To count the number of proliferating cells an antibody versus phosphorylated 
Ser10 in the tails of histone H3 (PHH3), a well-studied marker of cell 
mitosis, was used (Hans and Dimitrov 2001). Since neuroinflammation has 
been suggested to contribute to the reduced neurogenesis after radiotherapy 
(Monje et al. 2002), we also wanted to count the number of microglia. 
Microglia are the resident macrophages of the brain that serve both glial (e.g. 
monitoring of synapses and synapse pruning) and immune-related functions 
(e.g. immune surveillance, phagocytosis, removal of apoptotic and necrotic 
cells, regulation of inflammation) (Nimmerjahn et al. 2005, Schlegelmilch et 
al. 2011). They develop from embryonal yolk sac myeloid progenitors and 
enter into the brain very early in embryonic development (Ginhoux et al. 
2010). We used the ionized calcium-binding adapter molecule 1 (Iba1) 
monoclonal antibody as a microglia marker. The choice of antibody dilutions 
was based on a separate staining experiment. Several different antibody 
dilutions were tested, and the optimal dilution for cell counting was chosen.  
Counting was performed in two stained sections per animal, one from 5.3 
mm (for the SVZ) and one from 1.6 mm (for the hippocampus) rostral to the 
vertical zero plane, according to an atlas of rat brain anatomy in P9 rats 
(Sherwood and Timiras 1970) (Figure 8). The SVZ and GCL areas (including 
the SGZ), as well as the length of the SGZ, in both the ipsi- and contralateral 
hemispheres were traced and measured using Stereo Investigator 6.0 (MBF 
Bioscience, VT, USA). The examiner was blinded to the randomization 
group. In a separate experiment we explored the effect on blood glucose 
levels from eight hours of fasting. P9 rats were randomized to two treatment 
groups and one control group. The treatment groups were anaesthetized and 
put in chambers submerged in temperature-controlled water baths for eight 
hours, replicating the conditions from the first irradiation experiment (but 
without being irradiated). The control animals were anaesthetized and then 
returned to their biological dam. The body temperature was measured after 
1.5, 4, and 8 hours. After eight hours the animals were decapitated and blood 
was collected in a capillary tube from the neck vessels. Blood glucose was 
analyzed immediately in a blood analyzer. For further details regarding 
methods see Paper IV.  
Comments 
The brain development in P9 rats corresponds to an infant in humans (Semple 
et al. 2013). Since radiotherapy (especially craniospinal radiotherapy) seldom 
is used in children below 3-4 years of age, and practically never in newborn 
children, the choice of P9 rats is not ideal when translating our findings to 
children receiving radiotherapy. The rationale behind this choice was to make 
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the results comparable to the previous experiments, e.g. by Fukuda et al. 
(Fukuda et al. 2005). The single dose of ionizing radiation is also different 
from the radiotherapy practice in humans, where the total dose is delivered in 
multiple daily fractions, (usually every week-day, over a period of weeks). 
We could not replicate this however, for different practical reasons: 1) 
multiple procedures are more stressful for the animals, 2) the risk of 
introducing an infection to the animal facility increases when bringing them 
back and forth, 3) multiple sedations using tribromoethanol is not 
recommended due to its inflammatory properties. 
5.2.1 Statistical analysis 
One-way ANOVA followed by Sidak´s multiple comparison test was used to 
compare irradiated hemispheres from the normothermia and hypothermia 
groups with the control group. The significance level was set to p=0.05. The 
same analysis was used to compare the non-irradiated hemispheres between 
groups. GraphPad Prism version 7 for Windows (GraphPad Software, CA, 
USA), was used for statistical analyses. 
5.3 Results (Paper IV) 
5.3.1 Temperature, body weight, and blood glucose 
The hypothermia group had, as expected, a significantly lower body 
temperature (32.2°C) eight hours after irradiation, although the target rectal 
temperature of 30°C was not quite achieved. There was no significant 
difference in body temperature between the animals in the normothermia 
group and the non-irradiated control group. The groups did not differ 
significantly in body weight. The blood glucose levels decreased in the 
irradiated groups compared to controls, due to the eight-hour separation from 
the dam, but there was no significant difference between the normo- and 
hypothermia groups. 
5.3.2 Effects on the hippocampus (GCL and SGZ) 
The GCL area and SGZ length decreased significantly in all irradiated 
hemispheres compared to control animals, whereas the non-irradiated 
hemispheres were unaffected. There was no significant difference in GCL 
size or SGZ length between the irradiated hemispheres in the hypothermia 
and normothermia groups. The (absolute) number of proliferating cells 
(phospho-Histone H3+, Figure 9A) in the SGZ was significantly higher 
(x2.5) in the control group compared to the irradiated groups, but did not 
differ between the normo- and hypothermia groups (Figure 9B). There was a 
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non-significant trend towards lower relative numbers of proliferating cells 
(phospho-Histone H3+ cells/mm SGZ) after irradiation when comparing the 
control group versus the hypothermia group (p=0.053), and versus the 
normothermia group (p=0.075), but not between the two treatment groups 
(mean difference 0.04, 95 % CI -0.47 to 0.55, p=1.0, not shown). 
Furthermore, there was no difference in the number of microglia (Iba1+ cells, 
figure 9C) in the GCL, neither in absolute numbers (Figure 9D), nor in cell 
density (not shown), between treatment groups or compared to the control 
group. 
 Figure 9. A) Phospho-Histone H3 positive cells (arrows) in the subgranular zone (SGZ) of 
the hippocampal granule cell layer (GCL). B) Proliferating (phospho-histone H3+) cells in 
the SGZ, in the irradiated hemispheres of treatment groups and controls. C) Iba1 positive 
cells (arrows) in the hippocampus. D) Microglia (Iba1+ cells) cell count in the GCL between 
randomization groups. Boxplots with the interquartile range (IQR) and median, and Tukey 
style whiskers (i.e. extended to the most extreme data point that is no more than 1.5 × IQR 
from the edge of the box). IR irradiated, n.s. not significant (p >0.3). 
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5.3.3 Effects on the subventricular zone 
The combined size of the SVZ and the RMS was significantly smaller in the 
irradiated hemispheres of both the normothermia group and the hypothermia 
group, compared to the control group (Figure 10A). Furthermore, this area 
differed also between the normo- and the hypothermia groups, with a 
significantly larger size in the hypothermia group (mean 0.05 mm2 vs 0.07 
mm2, 95 % CI 0.001 to 0.04, p<0.05, Figure 10A). 
Figure 10. A) The combined area of the subventricular zone and the rostral migratory stream 
(SVZ+RMS) in the irradiated hemispheres of the treatment groups, and in controls. B) For 
comparison, the areas of the non-irradiated (contralateral) hemispheres were also measured. 
C) The SVZ proper (i.e. without the RMS), was severely reduced in the normothermia group 
after irradiation, but was unchanged in the hypothermia group, compared to controls. D) The 
RMS was reduced after irradiation, but did not differ between treatment groups 
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The corresponding areas in the non-irradiated hemispheres were not different 
in size from control areas (Figure 10B). When the SVZ was measured 
separately, excluding the RMS (SVZ proper), the difference between the 
treatment groups was even more pronounced, with a 50 % reduction in SVZ 
size in the normothermia group compared to controls (0.012 mm2 vs 0.023 
mm2 , 95 % CI 0.003 to 0.02, p<0.01). This reduction was completely 
prevented in the hypothermia group (0.022 mm2 vs 0.023 mm2 in controls, 
95% CI -0.007 to 0.008, p=1.0, Figure 10C). The RMS decreased to mean 43 
% of controls after irradiation (p<0.001), but did not differ significantly 
between the normo- and hypothermia groups (Figure 10D). 
The number of proliferating (phospho-histone H3+) cells was reduced by 
more than half in the irradiated normothermic SVZ, but this loss of 
proliferating cells was prevented in the hypothermic group (Figure 11A). 
Given the larger SVZ size in the irradiated hypothermia group, the cell 
density was however not significantly different from the irradiated 
normothermia group (Figure 11B). 
The absolute numbers of microglia (Iba1+ cells) in the SVZ decreased in 
the irradiated groups compared to controls, more significantly in the 
hypothermia group than the normothermia group, although the difference 
between the treatment groups was not significant (Figure 11C). Due to the 
preservation of SVZ area in the hypothermia group, there was a lower 
density of microglia in the irradiated SVZ of the hypothermia group 
compared to both the normothermia group (Figure 11D), and controls. 
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Figure 11. A) Absolute cell count of proliferating cells (phospho-histone H3+) in the 
subventricular zone (SVZ), compared between randomization groups. B) Cell density of 
proliferating (phospho-histone H3+) cells in the SVZ proper. The cell density did not differ 
between normothermia and hypothermia groups, probably due to the preserved, relatively 
larger SVZ in the hypothermia group. C) Microglia (Iba1+) cells in the SVZ+RMS compared 
between groups. D) Microglia (Iba1+) cell density in the SVZ+RMS was lower in the 
hypothermia group, compared to both the normothermia group and controls, probably due to 
the preserved, relatively larger SVZ in the hypothermia group. Boxplots showing the 
interquartile range (IQR) and median, with Tukey style whiskers (i.e. extended to the most 
extreme data point that is no more than 1.5 × IQR from the edge of the box). IR irradiated, 
n.s. not significant (p > 0. 3) 
Magnus Sabel 
77 
5.4 Discussion (Paper IV)  
In this animal model, young (P9) rats were randomized to a control group, or 
a treatment group consisting of hypo- or normothermia for eight hours 
immediately after a single fraction of hemi-brain irradiation. We found a 
protective effect from hypothermia on the SVZ area and the proliferative cell 
population in the SVZ, but no protection of the hippocampal dentate gyrus, 
one week post radiation.  
The reason for this selective protection is unclear, although consistent with 
previous findings (Fukuda et al. 2005). It could due to different sensitivities 
to irradiation, or differences in cell turn-over between the regions. This is 
supported by previous finding of differential dynamics between the SVZ and 
the GCL in the juvenile rat brain after irradiation, such that the SVZ 
recovered with time whereas the GCL did not (Hellström et al. 2009). It is 
conceivable that hypothermia in some way can enhance the recovery process 
of the SVZ. Another speculative hypothesis is that the close proximity of the 
SVZ to the CSF contributes to a less toxic environment after irradiation, as 
discussed in Paper IV. It is also possible that NPCs in the hippocampus are 
more vulnerable to stress compared to their SVZ counterpart, and that stress 
from hypothermia could counter the protective effect. In a study of the effect 
of longer-term hypothermia (30˚C for 24 h) on neurogenesis, cell 
proliferation was reduced in the hippocampus but not in the SVZ, possibly 
mediated by a stress-induced increase in corticosteroid levels (Kanagawa et 
al. 2006).  
Although the body temperatures in the hypothermia group reached 
hypothermic levels (mean body temperature 32.2˚C), the target temperature 
of 30˚C was not achieved. During the experiment, it was observed that the 
animals tended to clump together in the temperature-controlled container, 
something that probably helped them preserve body heat and lessened the 
cooling effect. We did however, reach the same hypothermic temperature as a 
previous study, but for twice as long, and compared to the previous study we 
found a more pronounced protective effect on the SVZ, post-irradiation 
(Fukuda et al. 2005). This indicates that hypothermia duration could be an 
important factor. The lower cell density of Iba1+ cells in the SVZs of the 
hypothermia group could indicate that hypothermia influences the 
inflammatory response after irradiation, leading to improved NPC 
survival/proliferation in the SVZ, although further studies are needed.  
The RMS did not seem to benefit from hypothermia in the same way as the 
SVZ. Although the border between these two areas is somewhat arbitrary, 
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this might reflect an underlying mechanism yet to be elucidated. A 
hypothesis could be that although the proliferative capacity of the SVZ was 
benefited by hypothermia, the previously reported negative effect of 
irradiation on the RMS  preventing the migration of neuroblasts  was 
unaffected (Achanta et al. 2012). 
Both irradiated groups had a lower mean blood glucose level after eight hours 
compared to controls, but there was no difference in blood glucose levels 
between the normo- and hypothermia groups that could explain the difference 
in SVZ areas. Furthermore, the GCL and SVZ areas in the non-irradiated 
(contralateral) hemispheres were not reduced compared to controls. It is 
therefore unlikely that blood glucose levels (or other metabolic changes due 
to fasting), can explain the difference in SVZ areas. 
The strengths of this study is the randomized design with blinded evaluation 
of the effect of hypothermia on the proliferative areas of the rodent brain. A 
limitation of our study is that we studied the potential protective effect of 
hypothermia at one time point only, and that we did not characterize the 
proliferating cells further. However, in a stroke model using adult rats, the 
size of the SVZ reflected the number of proliferating cells, indicating that 
SVZ size could be used as a marker of SVZ precursor proliferation (Parent et 
al. 2002).  
It may be that hypothermia delayed the detrimental effect on the SVZ area 
and that, over time, the area would decrease in a similar way as it did in the 
irradiated normothermia group. It is possible however, that hypothermia 
protected the NPC population in the SVZ (through anti-apoptosis, anti-
oxidation, or anti-inflammatory mechanisms), leaving a greater number of 
viable proliferating cells to repopulate the area. The latter scenario is 
supported by the combined findings of a larger preserved SVZ area, together 
with higher numbers of proliferating cells in the hypothermia treated group. 
This however, needs to be confirmed in future studies.  
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6 FINAL CONCLUSIONS AND FUTURE 
PERSPECTIVES 
The poor survival after medulloblastoma relapse found in Paper I is 
consistent with previous findings, and treatment for recurrent 
medulloblastoma continues to be a major clinical challenge. In isolated 
relapses, surgery can be beneficial. Surgery or biopsy should also be 
encouraged to verify the diagnosis of recurrent disease vs SMN or even non-
malignant MRI findings. International collaborative trials for recurrent 
medulloblastoma are needed and should be encouraged. These should 
preferably be based on biological sampling of recurrent tumors, and use the 
results to guide therapy. Tumor biopsy in that context is less ethically 
problematic, since the procedure leads to an immediate benefit for the patient 
(guided therapy), as well as the research community (more knowledge). 
Targeted therapy could be a way forward, e.g. using inhibitors of the sonic 
hedgehog pathway in SHH-MB, but the long term side effects of these new 
therapies are yet unknown. For example, the sonic hedgehog pathway is an 
important stimulating factor for neurogenesis the SVZ and GCL (Ahn and 
Joyner 2005), which raises concerns that SHH-inhibition could adversely 
affect normal brain function.  
The best way to handle relapses is of course to prevent them from happening. 
Research in resistance mechanisms is therefore important. Continued 
research in tumor (molecular) biology will hopefully provide further insight 
into how tumor cells avoid being killed by therapy, and how to best close 
their escape routes. As an example, Lithium treatment of radioresistant TP53 
mutant medulloblastoma cell lines sensitized the tumor cells to radiation 
through activation of the WNT pathway (Zhukova et al. 2014). Interestingly, 
Lithium did not activate WNT signaling in normal neuronal stem cells, and 
consequently their sensitivity to radiation was not enhanced (Zhukova et al. 
2014). In fact, evidence suggests Lithium could have a protective effect on 
hippocampal neurogenesis after irradiation, and reduce cognitive side effects 
(Zhou et al. 2017).  
Finding effective ways to mitigate the long term side effects after childhood 
brain tumor treatment is important, since they can have a severe impact on 
the survivors’ daily life. In addition, the number or survivors increase every 
year. There is growing evidence that exercise is beneficial to cognition, and 
exercise interventions are an interesting option for this patient group. But 
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there are challenges in finding interventions that are easily managed, fun to 
do, and can be performed on a long term basis. Interventions should probably 
be a combination of different activities, varying over time, to enhance 
participation and reduce attrition. The value of active video gaming deserves 
further exploration, and future research should focus on games that stimulate 
both physical activity and cognition, e.g. dance games. Group activities e.g. 
real life dance classes, could be considered, as well as methods of proven 
benefit, e.g. computerized working memory training with Cogmed. 
Inconvenience in travelling to the cancer center, e.g. after school hours, can 
hamper clinic-based interventions (Patel et al. 2009), and home-based 
interventions are therefore preferable.  
Support by Internet coaching is a resource efficient way of doing studies, but 
perhaps not easily transferred to large-scale clinical practice. Building 
Internet-based communities of brain tumor survivors could however be a 
method to stimulate rehabilitation activities, with the added value of 
decreasing social isolation. In view of the rapid technical development, 
already available virtual reality solutions will probably soon be less 
expensive, and could be an interesting option to explore further. 
Using hypothermia after radiotherapy to mitigate the harmful effects on 
neurogenesis needs further study before it can be used in a clinical setting. 
Both the functional and long term effects of the findings in Paper IV need to 
be investigated in animal studies, as well as the effect of hypothermia on 
brain tumors. Since radiotherapy is given over a period of weeks, the method 
has obvious practical challenges as well, although not unsurmountable 
provided the gain from the intervention is large enough. 
 
6.1 Concluding remarks 
In response to specific aims 
I. Long term survival after treatment for standard risk 
medulloblastoma has improved over the years, now reaching 
an estimated 10-year EFS and OS of ~80 %. After a median 
follow up of 7.4 years there was no difference in survival 
between treatment arms in the HIT-SIOP PNET4 trial. The 
prognosis after relapse however, was very poor, with a 
median OS of 1.5 years after relapse and a disappointing 5-
year OS of 6 %, irrespective of relapse treatment. Recurrent 
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tumors appeared at a median interval of 26 months from 
primary diagnosis, with 8 % late relapses (> 5 years after 
primary diagnosis). No benefit from HDSCR or 
radiotherapy was detected, but relapse treatments were 
diverse, and therefore difficult to evaluate. Patients with 
isolated posterior fossa relapses survived longer compared to 
patients with other relapse patterns. In selected cases, 
surgery seemed to be of benefit. The majority of relapses 
however, were metastatic within the CNS. The histological 
subgroup or biological factors (at primary diagnosis) had no 
impact on time in first remission, relapse pattern, or survival 
after relapse.  
 
II. An intervention with active video gaming and regular on-
line coaching achieved an enjoyable, near daily exercise of 
moderate intensity in pediatric brain tumor survivors. The 
method was feasible and compliance was good, but the 
overall physical activity levels were not significantly 
increased. 
III. No significant improvement was found in cognitive test 
scores after AVG, but the evaluation was limited by the 
small sample size. Clinically important improvements were 
found in motor function (body coordination) and ADL 
abilities. Continued research should be encouraged. 
 
IV. Post-irradiation moderate hypothermia for eight hours 
protected neurogenesis in the SVZ, but not in the 
hippocampus, in a rodent model. The mechanism for the 
protective effect and the reason for the selective effect on the 
neurogenic areas needs further study, as well as the effect of 
post-irradiation hypothermia on brain tumors. 
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7 ERRATA 
Paper I: On page 3, the second last sentence on the page should read: 
“There was information on CSF cytology in 61/72 patients.” 
On page 4: Surgery was performed in 18 cases and radiotherapy was given to 
16 patients, as indicated in Table 1.  
Paper III: In the Table 2 legend at page 8, the first row should read: “t =T-
score: mean=50, SD=10; s= standard score: mean=10, SD=3, IQ: mean=100, 
SD=15” 
In Table 3, page 9, the p-value for the change in motor score should be 
p=0.0122.
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